

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>A review of advances in the understanding of... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-905/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-905" />
    
            <meta name="description" content="Read the original article in full on F1000Research: A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies" />
    
            <meta name="og:title" content="F1000Research Article: A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies.">
            <meta name="og:description" content="Read the latest article version by Susan Yung, Desmond YH Yap, Tak Mao Chan, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="24760">
            <meta name="article-id" content="22438">
            <meta name="dc.title" content="A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies">
            <meta name="dc.description" content="Lupus nephritis is an important cause of both acute kidney injury and chronic kidney disease that can result in end-stage renal disease. Its pathogenic mechanisms are characterized by aberrant activation of both innate and adaptive immune responses, dysregulation of inflammatory signaling pathways, and increased cytokine production. Treatment of lupus nephritis remains a challenging issue in the management of systemic lupus erythematosus since the clinical presentation, response to treatment, and prognosis all vary considerably between patients and are influenced by ethnicity, gender, the degree of chronic kidney damage, pharmacogenomics, and non-immunological modulating factors. Elucidation of the various immunopathogenic pathways in lupus nephritis has resulted in the development of novel therapies, including biologics that target specific antigens on B lymphocytes to achieve B cell depletion, agents that modulate B cell proliferation and development, drugs that block co-stimulatory pathways, drugs that target T lymphocytes primarily, and therapies that target complement activation, signaling pathways, pro-inflammatory cytokines, and neutrophil extracellular traps. This review will discuss recent advances in the understanding of disease pathogenesis in lupus nephritis in the context of potential emerging therapies.">
            <meta name="dc.subject" content="lupus nephritis, lupus nephritis pathogenesis, inflammation, B cell depletion, emerging therapies">
            <meta name="dc.creator" content="Yung, Susan">
            <meta name="dc.creator" content="Yap, Desmond YH">
            <meta name="dc.creator" content="Chan, Tak Mao">
            <meta name="dc.date" content="2020/08/04">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.22438.1">
            <meta name="dc.source" content="F1000Research 2020 9:905">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="lupus nephritis">
            <meta name="prism.keyword" content="lupus nephritis pathogenesis">
            <meta name="prism.keyword" content="inflammation">
            <meta name="prism.keyword" content="B cell depletion">
            <meta name="prism.keyword" content="emerging therapies">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/08/04">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="905">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.22438.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-905">
            <meta name="citation_title" content="A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies">
            <meta name="citation_abstract" content="Lupus nephritis is an important cause of both acute kidney injury and chronic kidney disease that can result in end-stage renal disease. Its pathogenic mechanisms are characterized by aberrant activation of both innate and adaptive immune responses, dysregulation of inflammatory signaling pathways, and increased cytokine production. Treatment of lupus nephritis remains a challenging issue in the management of systemic lupus erythematosus since the clinical presentation, response to treatment, and prognosis all vary considerably between patients and are influenced by ethnicity, gender, the degree of chronic kidney damage, pharmacogenomics, and non-immunological modulating factors. Elucidation of the various immunopathogenic pathways in lupus nephritis has resulted in the development of novel therapies, including biologics that target specific antigens on B lymphocytes to achieve B cell depletion, agents that modulate B cell proliferation and development, drugs that block co-stimulatory pathways, drugs that target T lymphocytes primarily, and therapies that target complement activation, signaling pathways, pro-inflammatory cytokines, and neutrophil extracellular traps. This review will discuss recent advances in the understanding of disease pathogenesis in lupus nephritis in the context of potential emerging therapies.">
            <meta name="citation_description" content="Lupus nephritis is an important cause of both acute kidney injury and chronic kidney disease that can result in end-stage renal disease. Its pathogenic mechanisms are characterized by aberrant activation of both innate and adaptive immune responses, dysregulation of inflammatory signaling pathways, and increased cytokine production. Treatment of lupus nephritis remains a challenging issue in the management of systemic lupus erythematosus since the clinical presentation, response to treatment, and prognosis all vary considerably between patients and are influenced by ethnicity, gender, the degree of chronic kidney damage, pharmacogenomics, and non-immunological modulating factors. Elucidation of the various immunopathogenic pathways in lupus nephritis has resulted in the development of novel therapies, including biologics that target specific antigens on B lymphocytes to achieve B cell depletion, agents that modulate B cell proliferation and development, drugs that block co-stimulatory pathways, drugs that target T lymphocytes primarily, and therapies that target complement activation, signaling pathways, pro-inflammatory cytokines, and neutrophil extracellular traps. This review will discuss recent advances in the understanding of disease pathogenesis in lupus nephritis in the context of potential emerging therapies.">
            <meta name="citation_keywords" content="lupus nephritis, lupus nephritis pathogenesis, inflammation, B cell depletion, emerging therapies">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Susan Yung">
            <meta name="citation_author_institution" content="Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong">
            <meta name="citation_author" content="Desmond YH Yap">
            <meta name="citation_author_institution" content="Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong">
            <meta name="citation_author" content="Tak Mao Chan">
            <meta name="citation_author_institution" content="Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong">
            <meta name="citation_publication_date" content="2020/08/04">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="905">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.22438.1">
            <meta name="citation_firstpage" content="905">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-905/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-905.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=24760 /> <input type=hidden id=articleId name=articleId value=22438 /> <input type=hidden id=xmlUrl value="/articles/9-905/v1/xml"/> <input type=hidden id=xmlFileName value="-9-905-v1.xml"> <input type=hidden id=article_uuid value=0f84549e-a903-4c8b-bc81-b89fa4200693 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.22438.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.22438.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-905"
  },
  "headline": "A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies",
  "datePublished": "2020-08-04T14:43:18",
  "dateModified": "2020-08-04T14:43:18",
  "author": [
    {
      "@type": "Person",
      "name": "Susan Yung"
    },    {
      "@type": "Person",
      "name": "Desmond YH Yap"
    },    {
      "@type": "Person",
      "name": "Tak Mao Chan"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Lupus nephritis is an important cause of both acute kidney injury and chronic kidney disease that can result in end-stage renal disease. Its pathogenic mechanisms are characterized by aberrant activation of both innate and adaptive immune responses, dysregulation of inflammatory signaling pathways, and increased cytokine production. Treatment of lupus nephritis remains a challenging issue in the management of systemic lupus erythematosus since the clinical presentation, response to treatment, and prognosis all vary considerably between patients and are influenced by ethnicity, gender, the degree of chronic kidney damage, pharmacogenomics, and non-immunological modulating factors. Elucidation of the various immunopathogenic pathways in lupus nephritis has resulted in the development of novel therapies, including biologics that target specific antigens on B lymphocytes to achieve B cell depletion, agents that modulate B cell proliferation and development, drugs that block co-stimulatory pathways, drugs that target T lymphocytes primarily, and therapies that target complement activation, signaling pathways, pro-inflammatory cytokines, and neutrophil extracellular traps. This review will discuss recent advances in the understanding of disease pathogenesis in lupus nephritis in the context of potential emerging therapies."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-905",
            "name": "A review of advances in the understanding of lupus nephritis pathogenesis..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> A review of advances in the understanding of lupus nephritis pathogenesis... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=24760 data-id=22438 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22438.1" data-recommended="" data-doi="10.12688/f1000research.22438.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-905/v1/pdf?article_uuid=0f84549e-a903-4c8b-bc81-b89fa4200693" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-22438-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-22438-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-22438-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Yung S, Yap DY and Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):905 (<a class=new-orange href="https://doi.org/10.12688/f1000research.22438.1" target=_blank>https://doi.org/10.12688/f1000research.22438.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-22438-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=22438 id=track-article-signin-22438 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22438?target=/articles/9-905">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24760 /> <input name=articleId type=hidden value=22438 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Susan Yung<sup>*</sup>,&nbsp;</span><span class="">Desmond YH Yap<sup>*</sup>,&nbsp;</span><span class=""><a href="mailto:dtmchan@hku.hk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Tak Mao Chan</span></a><a href="https://orcid.org/0000-0002-3495-4051" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3495-4051</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Susan Yung<sup>*</sup>,&nbsp;</span><span class="">Desmond YH Yap<sup>*</sup>,&nbsp;</span><span class=""><a href="mailto:dtmchan@hku.hk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Tak Mao Chan</span></a><a href="http://orcid.org/0000-0002-3495-4051" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3495-4051</div></span></div> </div> <div class="authors extra-info"> <sup>*</sup> Equal contributors </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 04 Aug 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.22438.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong<br/> <p> <div class=margin-bottom> Susan Yung <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Desmond YH Yap <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Tak Mao Chan <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73471-68623></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73470-68622></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Lupus nephritis is an important cause of both acute kidney injury and chronic kidney disease that can result in end-stage renal disease. Its pathogenic mechanisms are characterized by aberrant activation of both innate and adaptive immune responses, dysregulation of inflammatory signaling pathways, and increased cytokine production. Treatment of lupus nephritis remains a challenging issue in the management of systemic lupus erythematosus since the clinical presentation, response to treatment, and prognosis all vary considerably between patients and are influenced by ethnicity, gender, the degree of chronic kidney damage, pharmacogenomics, and non-immunological modulating factors. Elucidation of the various immunopathogenic pathways in lupus nephritis has resulted in the development of novel therapies, including biologics that target specific antigens on B lymphocytes to achieve B cell depletion, agents that modulate B cell proliferation and development, drugs that block co-stimulatory pathways, drugs that target T lymphocytes primarily, and therapies that target complement activation, signaling pathways, pro-inflammatory cytokines, and neutrophil extracellular traps. This review will discuss recent advances in the understanding of disease pathogenesis in lupus nephritis in the context of potential emerging therapies. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> lupus nephritis, lupus nephritis pathogenesis, inflammation, B cell depletion, emerging therapies </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Tak Mao Chan (<a href="mailto:dtmchan@hku.hk">dtmchan@hku.hk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Tak Mao Chan </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> Studies undertaken by T. M. Chan’s group were funded by the RGC General Research Fund (HKU 7550/06M), UGC Matching Grant Scheme (Phases V and VI), the Department of Medicine Academic Activities Fund and kind donations from Mr C. S. Yung, Mr S. Ho, the Hui Hoy & Chow Sin Lan Charity Fund, and the family of Mr Hui Ming. S. Yung is supported by the Endowment Fund established for the 'Yu Chiu Kwong Professorship in Medicine' awarded to T. M. Chan and the Wai Hung Charitable Foundation Limited. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Yung S <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Yung S, Yap DY and Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):905 (<a href="https://doi.org/10.12688/f1000research.22438.1" target=_blank>https://doi.org/10.12688/f1000research.22438.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 04 Aug 2020, <b>9</b>(Faculty Rev):905 (<a href="https://doi.org/10.12688/f1000research.22438.1" target=_blank>https://doi.org/10.12688/f1000research.22438.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 04 Aug 2020, <b>9</b>(Faculty Rev):905 (<a href="https://doi.org/10.12688/f1000research.22438.1" target=_blank>https://doi.org/10.12688/f1000research.22438.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d3524e169>Introduction</h2><p class="" id=d3524e172>Kidney involvement, termed lupus nephritis (LN), is one of the most severe forms of organ involvement in systemic lupus erythematosus (SLE) as reflected by the associated morbidities, its detrimental effects on patient and kidney survival, and the quantity of immunosuppressive agents required for treatment<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. The resultant chronic kidney damage and the exposure to toxic medications are also significant contributors to reduced survival of patients even after successful treatment of active nephritis. The pathogenesis of LN encompasses a loss of self-tolerance, aberrant activation of both innate and adaptive immune responses, autoantibody production, and immune-mediated kidney injury. LN is characterized by episodic flares separated by variable durations of disease quiescence. Even when immunosuppressive treatments are successful in inducing remission, the cumulative kidney damage resulting from repeated nephritic flares, as evident from glomerulosclerosis, fibrous crescents, tubular atrophy, and interstitial fibrosis in the kidney biopsy, portends progressive chronic kidney disease eventually culminating in end-stage renal failure<sup><a href="#ref-3">3</a></sup>. The goals of clinical management therefore include early detection and prompt and effective treatment of acute nephritic flares as well as the prevention of relapses. The efficacy and tolerability of current immunosuppressive treatments for LN vary between patients and are influenced by multiple factors including race and renal reserve. In addition, corticosteroids remain a mainstay of treatment but are associated with considerable short-term and long-term toxicities related to non-specific anti-inflammatory and immunosuppressive actions. It is against this background that the search for novel therapies has continued with the aim of adding new treatments with increased levels of safety, often related to increased specificity in intercepting crucial pathogenic pathway(s), to the therapeutic armamentarium. This review presents a brief overview of recent knowledge in the pathogenesis of LN in the context of potential emerging therapies (<a href="#f1">Figure 1</a>) (<a href="#T1">Table 1</a>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/24760/3afe37e5-0bab-46f3-b18d-5311754d922e_figure1.gif"><img alt="3afe37e5-0bab-46f3-b18d-5311754d922e_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/24760/3afe37e5-0bab-46f3-b18d-5311754d922e_figure1.gif"></a><div class=caption><h3>Figure 1. Schematic diagram showing the immunopathogenic pathways leading to kidney damage in lupus nephritis and emerging novel therapies targeting specific pathways.</h3><p id=d3524e202>Ab, antibody; APC, antigen presenting cell; APRIL, a proliferating-inducing ligand; BAFF, B cell activating factor; BAFFR, B cell activating factor receptor; BCMA, B cell maturation antigen; BTK, Bruton’s tyrosine kinase; C3, complement 3; C5, complement 5; CD, cluster of differentiation; CNI, calcineurin inhibitor; ds, double-stranded; FKBP12, FK506-binding protein; IFN, interferon; IFNα/βR, interferon-α/β receptor; JAK, Janus kinase; MHC, major histocompatibility complex; mTOR, mammalian or mechanistic target of rapamycin; NETs, neutrophil extracellular traps; NFATC2, nuclear factor of activated T cells 2; TACI, transmembrane activator and calcium modulator and cyclophilin ligand interactor; TCR, T cell receptor; TYK2, tyrosine kinase-2.</p></div></div><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Examples of novel therapies for systemic lupus erythematosus targeting specific cells or pathogenic pathways.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d3524e220 class=n-a></a><thead><a name=d3524e222 class=n-a></a><tr><a name=d3524e224 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d3524e226 class=n-a></a>Target</th><th align=left colspan=1 rowspan=1><a name=d3524e229 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1><a name=d3524e232 class=n-a></a>Study outcomes and ongoing trials</th></tr></thead><tbody><a name=d3524e237 class=n-a></a><tr><a name=d3524e239 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e240 class=n-a></a><b>B cells (CD20)</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e244 class=n-a></a>Rituximab (chimeric anti-CD20<br class=br>mAb)<br class=br><br class=br>Obinutuzumab (humanized<br class=br>type 2 anti-CD20 mAb)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e254 class=n-a></a>•&nbsp;&nbsp;&nbsp;Data from the LUNAR trial showed that rituximab, when added to standard induction treatment, did not show renal<br class=br>benefits in active LN patients<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;May have a role in refractory or frequently relapsing disease, high-risk patient groups (e.g. Afro-Americans), or<br class=br>corticosteroid minimization<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;A phase II trial (NOBILITY, NCT02550652) showed that obinutuzumab, when added to background immunosuppression<br class=br>comprising mycophenolate and corticosteroids, increased the rate of achieving primary and secondary efficacy<br class=br>endpoints, possibly related to a rapid and complete depletion of peripheral, memory, and naïve B cell subsets and plasmablasts</td></tr><tr><a name=d3524e272 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e273 class=n-a></a><b>B cells (CD19)</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e277 class=n-a></a>XmAb5871 (humanized anti-<br class=br>CD19 mAb)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e282 class=n-a></a>•&nbsp;&nbsp;&nbsp;A phase II clinical trial (NCT02725515) showed that XmAb5871 treatment in non-organ-threatening SLE patients did not<br class=br>meet the primary endpoint (no LOI) but achieved the secondary endpoints (time-to-LOI and safety)</td></tr><tr><a name=d3524e287 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e288 class=n-a></a><b>B cells (BAFF/</b><br class=br><b>APRIL)</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e295 class=n-a></a>Belimumab (humanized anti-<br class=br>BAFF mAb)<br class=br><br class=br><br class=br><br class=br>Tabalumab (humanized<br class=br>mAb against soluble and<br class=br>membrane-bound BAFF)<br class=br><br class=br>Atacicept (fusion protein<br class=br>between TACI and Fc portion<br class=br>of IgG)<br class=br><br class=br>Telitacicept (novel recombinant<br class=br>TACI-Fc fusion protein)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e322 class=n-a></a>•&nbsp;&nbsp;&nbsp;Data from BLISS-52 and -76 trials showed efficacy in SLE patients, but patients with moderate-to-severe LN or<br class=br>neuropsychiatric complications were excluded<br class=br>•&nbsp;&nbsp;&nbsp;Results from BLISS-LN (NCT01639339) showed that patients with active LN treated with belimumab plus standard<br class=br>induction treatment had superior renal response compared with placebo<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;RCT data from ILLUMINATE-1 and -2 showed that tabalumab did not meet primary efficacy endpoint SRI-5 at 52 weeks<br class=br>in patients with active SLE without nephritis; pooled data from these two RCTs also did not show any renal benefits<br class=br><br class=br><br class=br>•&nbsp;&nbsp;&nbsp;A phase II/III clinical trial in patients with active LN (APRIL-LN; NCT00573157) was terminated early owing to severe<br class=br>infective complications associated with hypogammaglobulinemia<br class=br><br class=br><br class=br>•&nbsp;&nbsp;&nbsp;A phase IIb study (NCT02885610) showed that telitacicept in combination with standard therapy met its primary<br class=br>endpoints in active SLE patients without nephritis</td></tr><tr><a name=d3524e349 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e350 class=n-a></a><b>B cells</b><br class=br><b>(Proteasome)</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e357 class=n-a></a>Bortezomib<br class=br><br class=br><br class=br><br class=br>Ixazomib<br class=br><br class=br><br class=br>KZR-616</td><td colspan=1 rowspan=1 valign=top><a name=d3524e369 class=n-a></a>•&nbsp;&nbsp;&nbsp;Preliminary data showed efficacy in patients with refractory LN but was associated with high rates of treatment<br class=br>discontinuation because of poor drug tolerability<br class=br>•&nbsp;&nbsp;&nbsp;A phase II study (NCT02102594) is currently underway to investigate its use in SLE patients<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;Ixazomib shows fewer neurological side effects compared to bortezomib, and a phase II study (NCT02176486) is<br class=br>currently underway to investigate its use in LN patients<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;Phase I data from MISSION (NCT03393013) suggest that KZR-616 is well tolerated in SLE patients with or without<br class=br>nephritis; a phase II study has been initiated to investigate its use in LN patients</td></tr><tr><a name=d3524e387 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e388 class=n-a></a><b>B cells (Aiolos</b><br class=br><b>and Ikaros)</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e395 class=n-a></a>Iberdomide (CC-220) (a<br class=br>cereblon modulator targeting<br class=br>Ikaros and Aiolos)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e402 class=n-a></a>•&nbsp;&nbsp;&nbsp;A phase IIa study (NCT02185040) showed that iberdomide (CC-220) reduced various B cell subsets and improved<br class=br>arthritis and CLASI activity scores in SLE patients</td></tr><tr><a name=d3524e408 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e409 class=n-a></a><b>T cells</b><br class=br><b>(Calcineurin)</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e416 class=n-a></a>Tacrolimus<br class=br><br class=br><br class=br><br class=br>Voclosporin </td><td colspan=1 rowspan=1 valign=top><a name=d3524e424 class=n-a></a>•&nbsp;&nbsp;&nbsp;Results from clinical trials in LN patients showed that dual or triple immunosuppressive regimens that included<br class=br>tacrolimus were associated with comparable or higher short-term response rate and often more rapid reduction of<br class=br>proteinuria compared to treatment regimens that did not include a CNI<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;Improved pharmacokinetic profile compared to tacrolimus<br class=br>•&nbsp;&nbsp;&nbsp;A phase II study (AURA-LV; NCT02141672) in active LN patients showed that voclosporin (high or low dose) when<br class=br>combined with corticosteroids and MMF showed superior renal response rates compared with corticosteroids and MMF<br class=br>treatment<br class=br>•&nbsp;&nbsp;&nbsp;A phase III study (AURORA; NCT03021499) reported that voclosporin (23 mg bid) in combination with corticosteroids<br class=br>(rapid tapering) and MMF in active LN patients resulted in better renal response rates and proteinuria suppression<br class=br>compared with control treatment comprising corticosteroids and MMF</td></tr><tr><a name=d3524e447 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e448 class=n-a></a><b>Co-stimulatory</b><br class=br><b>pathways (CTLA4)</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e455 class=n-a></a>Abatacept </td><td colspan=1 rowspan=1 valign=top><a name=d3524e458 class=n-a></a>•&nbsp;&nbsp;&nbsp;Phase II data showed that induction therapy for active proliferative LN with abatacept combined with corticosteroids<br class=br>and MMF improved proteinuria and serological parameters but did not meet primary endpoint (time to complete renal<br class=br>response) for superiority<br class=br>•&nbsp;&nbsp;&nbsp;The phase III ALLURE trial reported that the addition of abatacept to standard of care in active LN patients did not<br class=br>increase renal response rate, but those who received abatacept appeared to show more rapid and more sustained<br class=br>proteinuria reduction</td></tr><tr><a name=d3524e471 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e472 class=n-a></a><b>Co-stimulatory</b><br class=br><b>pathways (CD40)</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e479 class=n-a></a>BI655064 (humanized anti-<br class=br>CD40 mAb)<br class=br><br class=br>CFZ533 (humanized anti-CD40<br class=br>mAb)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e489 class=n-a></a>•&nbsp;&nbsp;&nbsp;A phase II clinical trial (NCT02770170) is currently underway to investigate the efficacy and safety of BI655064<br class=br>in combination with standard of care therapy in active LN patients<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;A phase II study (NCT03610516) is currently underway to investigate its use in LN patients who show persistent<br class=br>significant proteinuria after standard induction treatments</td></tr><tr><a name=d3524e499 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e500 class=n-a></a><b>Co-stimulatory</b><br class=br><b>pathways (CD40L)</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e507 class=n-a></a>Dapirolizumab pegol<br class=br>(pegylated Fab anti-CD40L)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e512 class=n-a></a>•&nbsp;&nbsp;&nbsp;A recent phase II trial (NCT02804763) showed numerically higher response rates and greater improvement in several<br class=br>clinical outcome measures compared to placebo but did not meet the primary endpoint (BICLA response rates at 24<br class=br>weeks)</td></tr><tr><a name=d3524e519 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e520 class=n-a></a><b>mTOR</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e524 class=n-a></a>Sirolimus </td><td colspan=1 rowspan=1 valign=top><a name=d3524e527 class=n-a></a>•&nbsp;&nbsp;&nbsp;A recent single-arm phase I/II study (NCT00779194) showed that sirolimus treatment in active SLE patients without<br class=br>nephritis or life-threatening lupus complications had decreased disease activity scores and T cell profile indicating a<br class=br>less pro-inflammatory phenotype<br class=br>•&nbsp;&nbsp;&nbsp;Data from our group show that sirolimus may have a role in LN management, especially in LN patients who do not<br class=br>tolerate other treatments, and may be considered especially in patients with a history of malignancy</td></tr><tr><a name=d3524e538 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e539 class=n-a></a><b>Type I IFNR</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e543 class=n-a></a>Anifrolumab (humanized mAb<br class=br>to type I IFNR)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e548 class=n-a></a>•&nbsp;&nbsp;&nbsp;Data from phase III TULIP-1 and -2 trials showed clinical benefits of anifrolumab treatment in moderate-to-severe SLE<br class=br>patients with active disease, especially in those with high type I IFN signatures<br class=br>•&nbsp;&nbsp;&nbsp;Decreased NET formation</td></tr><tr><a name=d3524e556 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e557 class=n-a></a><b>IL-23</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e561 class=n-a></a>Guselkumab (humanized anti-<br class=br>IL-23 mAb)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e566 class=n-a></a>•&nbsp;&nbsp;&nbsp;A forthcoming phase II study will investigate its application in LN</td></tr><tr><a name=d3524e569 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e570 class=n-a></a><b>IL-17</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e574 class=n-a></a>Secukinumab (humanized anti-<br class=br>IL-17 mAb)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e579 class=n-a></a>•&nbsp;&nbsp;&nbsp;A phase II clinical study (NCT04181762) is underway to investigate its role in patients with refractory LN</td></tr><tr><a name=d3524e582 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e583 class=n-a></a><b>IL-2</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e587 class=n-a></a>Low-dose IL-2</td><td colspan=1 rowspan=1 valign=top><a name=d3524e590 class=n-a></a>•&nbsp;&nbsp;&nbsp;One recent RCT (NCT02465580) showed that low-dose IL-2 treatment in active SLE patients did not meet its primary<br class=br>endpoint of SRI-4 at 12 weeks but achieved higher complete remission rates than placebo in patients with LN and was<br class=br>well tolerated</td></tr><tr><a name=d3524e597 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e598 class=n-a></a><b>JAK1</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e602 class=n-a></a>Baricitinib (JAK1/2 inhibitor)<br class=br><br class=br>PF-06700841 t(selective JAK1<br class=br>inhibitor)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e610 class=n-a></a>•&nbsp;&nbsp;&nbsp;A phase II RCT (NCT02708095) demonstrated efficacy in alleviating arthritis in active SLE patients<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;A phase IIb study (PF-06700841) will investigate a selective JAK1 inhibitor in moderate-to-severe active SLE patients<br class=br>without renal or cerebral involvement who show inadequate response to standard therapies<br class=br>•&nbsp;&nbsp;&nbsp;A phase II clinical trial on solcitinib (a selective JAK1 inhibitor) (NCT01777256) was discontinued owing to severe drug<br class=br>reaction with eosinophilia and systemic symptoms (DRESS) syndrome and hepatic function abnormalities</td></tr><tr><a name=d3524e622 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e623 class=n-a></a><b>TYK2</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e627 class=n-a></a>BMS-986165 (an oral selective<br class=br>TYK2 inhibitor)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e632 class=n-a></a>•&nbsp;&nbsp;&nbsp;BMS-986165 blocks signaling pathways of multiple cytokines (IL-12, IL-23, and type I IFN)<br class=br>•&nbsp;&nbsp;&nbsp;A phase II RCT (PAISLEY; NCT03252587) is underway to investigate its efficacy and safety in active SLE patients with<br class=br>joint and/or skin involvement</td></tr><tr><a name=d3524e639 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e640 class=n-a></a><b>BTK</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e644 class=n-a></a>Fenebrutinib (BTK inhibitor)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e647 class=n-a></a>•&nbsp;&nbsp;&nbsp;Results from a phase II RCT (NCT02908100) showed that fenebrutinib treatment in patients with moderate or severe<br class=br>active SLE was associated with a significant reduction in CD19+ B cells, anti-dsDNA levels, and BTK-dependent<br class=br>signature in plasmablasts, but the primary clinical efficacy endpoint (SRI-4) was not met</td></tr><tr><a name=d3524e655 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e656 class=n-a></a><b>Complement</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e660 class=n-a></a>APL-2 (synthetic peptide that<br class=br>binds C3 and C3b)<br class=br><br class=br>Eculizumab (anti-C5b<br class=br>monoclonal antibody)<br class=br><br class=br>LNP023 (factor B inhibitor)<br class=br><br class=br><br class=br>OMS721 (MASP-2 inhibitor)</td><td colspan=1 rowspan=1 valign=top><a name=d3524e678 class=n-a></a>•&nbsp;&nbsp;&nbsp;Data from a phase II clinical trial showed that APL-2 was well tolerated and treatment was associated with a reduction in<br class=br>urine protein excretion<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;Phase I study showed that eculizumab was well tolerated in SLE patients<br class=br>•&nbsp;&nbsp;&nbsp;Emerging data suggest efficacy in selected LN patients such as those with TMA or refractory nephritis<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;Phase II trial in patients with paroxysmal nocturnal hemoglobinuria and IgA nephropathy but has not been investigated<br class=br>in LN<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;Phase II study showed that OMS721 treatment of LN patients was associated with significant reduction in proteinuria<br class=br>and feasibility of steroid dose tapering</td></tr><tr><a name=d3524e699 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d3524e700 class=n-a></a><b>NETs</b></td><td colspan=1 rowspan=1 valign=top><a name=d3524e704 class=n-a></a>B cell depletion<br class=br><br class=br>Tofacitinib (JAK/STAT inhibitor)<br class=br><br class=br>Metformin</td><td colspan=1 rowspan=1 valign=top><a name=d3524e713 class=n-a></a>•&nbsp;&nbsp;&nbsp;SynBioSe study (NCT02284984) showed that combination treatment with rituximab and belimumab reduced NET<br class=br>formation in SLE patients<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;Phase I study will investigate the safety and tolerability of tofacitinib in SLE patients<br class=br><br class=br>•&nbsp;&nbsp;&nbsp;A study in Chinese patients (ChiCTR-TRC-12002419) showed that metformin added to conventional treatment for 12<br class=br>months in SLE patients with mild-to-moderate disease decreased SLEDAI score by over 50%<br class=br>•&nbsp;&nbsp;&nbsp;Metformin reduced NET formation in neutrophils stimulated with PMA and decreased IFN-α secretion in plasmacytoid<br class=br>dendritic cells</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d3524e735 class=n-a></a><p id=d3524e737> APRIL, a proliferating-inducing ligand; BAFF, B cell activating factor; BICLA, British Isles Lupus Assessment Group-based Combined Lupus Assessment; bid, <i>bis in die</i> (twice a day); BTK, Bruton’s tyrosine kinase; C3, complement 3; C5, complement 5; CLASI, cutaneous lupus erythematosus disease area and severity index; CNI, calcineurin inhibitor; CTLA4, cytotoxic T-lymphocyte-associated-antigen 4; DRESS, drug rash with eosinophilia and systemic symptoms; ds, double-stranded; IFN, interferon; IFNR, interferon receptor; Ig, immunoglobulin; IL, interleukin; JAK, Janus kinase; LN, lupus nephritis; LOI, loss of improvement; mAb, monoclonal antibody; MASP-2, mannan-binding lectin serine protease 2; MMF, mycophenolate mofetil; mTOR, mammalian or mechanistic target of rapamycin; NET, neutrophil extracellular trap; PMA, phorbol 12-myristate 13-acetate; RCT, randomized controlled trial; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; SRI, systemic lupus erythematosus responder index; STAT, signal transducer and activator of transcription; TACI, transmembrane activator and calcium modulator and cyclophilin ligand interactor; TMA, thrombotic microangiopathy; TYK2, tyrosine kinase 2.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3524e749>B lymphocytes in the pathogenesis of lupus nephritis</h2><p class="" id=d3524e752>The etiology of LN is complex and multi-factorial and involves the interplay between genetic predisposition and environmental and hormonal factors<sup><a href="#ref-4">4</a>–<a href="#ref-7">7</a></sup>. LN is characterized by the production of autoantibodies against a broad diversity of autoantigens, in particular against chromatin material such as double-stranded (ds) DNA and nucleosomes resulting from defective clearance of apoptotic material<sup><a href="#ref-8">8</a></sup>, and necrotic cells that release cellular components which may form neoantigens. The release of DNA/protein and RNA/protein from dying cells activates dendritic cells, monocytes, and macrophages through Toll-like receptor (TLRs), resulting in the secretion of pro-inflammatory mediators, such as interferon (IFN)-α, tumor necrosis factor (TNF)-α, and interleukin (IL)-6, which activate effector T cells and B cells. Aberrant T cell activation and the prolonged survival and maturation process of B cells result in increased numbers of autoreactive B cells, memory B cells, and plasma cells. Abnormalities in B cell biology in SLE include early entrance of immature, transitional, and naïve B cells to mature B cells, attributed in part through increased expression of B-cell-activating factor (BAFF), a cytokine that promotes B cell survival from late transitional stage to mature and memory B cells. FcγRIIIB expression is reduced in SLE patients compared to healthy subjects, resulting in the persistence of autoreactive B cells. Also, memory B cells in SLE patients show reduced FcγRIIB expression and a lower threshold for reactivation<sup><a href="#ref-9">9</a></sup>. B cells derived from SLE patients exhibit increased somatic hypermutation and class-switch recombination, resulting in enhanced pathogenicity of plasma cells<sup><a href="#ref-10">10</a>–<a href="#ref-12">12</a></sup>. Autoantibodies produced by plasma cells in LN patients are usually of the immunoglobulin (Ig) G subclass, and the isotype can be related to the nature of the respective antigen. For example, protein and polysaccharide antigens have been shown to induce IgG1 and IgG2, respectively<sup><a href="#ref-13">13</a></sup>. Also, pro-inflammatory cytokines such as IL-4 and IL-21 can induce isotype switching<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. In this regard, IgG1 and IgG3 bind FcγR more efficiently to trigger complement activation, downstream inflammatory processes, immune complex deposition, and tissue injury.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3524e792>Emerging therapies targeting B lymphocytes</h2><p class="" id=d3524e795>As described previously, B cells are promising therapeutic targets of LN since they are central to pathogenesis<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>. The pathogenic role of B cells is not just limited to autoantibody production but extends to antigen presentation, T cell activation and polarization, modulation of dendritic cell maturation, and cytokine secretion<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>. The survival and maturation of B cells at different stages of development depend on the delivery of survival and trophic signals through cell surface ligands such as BAFF, CD19, and CD20. These cell surface antigens may thus serve as therapeutic targets for B cell depletion in the treatment of SLE and LN.</p><div class=section><a name=d3524e812 class=n-a></a><h3 class=section-title>Rituximab</h3><p class="" id=d3524e817>CD20 is a specific B cell surface antigen that promotes differentiation and activation. It is expressed on immature, mature, and activated B cells and is absent on hematopoietic stem cells, pro-B cells, and plasma cells<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>. Rituximab is a type I chimeric IgG1 mouse/human monoclonal antibody directed against CD20, and it depletes B cells, thus diminishing their differentiation into plasma cells, and therefore decreases autoantibody production<sup><a href="#ref-19">19</a></sup>. Rituximab was originally approved for the treatment of relapsed or refractory, low-grade or follicular, CD20<sup>+</sup> B cell non-Hodgkin lymphoma, and its use has been extended to various autoimmune diseases such as rheumatoid arthritis, ANCA-associated vasculitis, and primary immune thrombocytopenic purpura<sup><a href="#ref-20">20</a></sup>. Crosslinking of CD20 molecules by rituximab induces the redistribution of CD20 into membrane microdomains known as lipid rafts and the formation of antigen–antibody complexes, leading to CD20<sup>+</sup> B cell apoptosis through three mechanisms, namely complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and, to a lesser extent, direct signaling through CD20. Rituximab eliminates peripheral B cells without suppressing their regeneration from B cell precursors, and, by sparing plasma cells, has no immediate effect on Ig level. In preclinical studies, treatment of New Zealand black and white, first generation (NZB/W F1) mice with anti-CD20 antibodies before the onset of proteinuria delayed disease onset, whereas treatment after onset of nephritis reduced disease progression, suggesting that B cells are critical to both the initiation and the maintenance of disease<sup><a href="#ref-21">21</a></sup>. There is also a subset-associated hierarchy of B cell sensitivity to depletion by rituximab, with peripheral blood B cells being the most sensitive, and B cells in the spleen, lymph node, or bone marrow being less sensitive, which could be related to relatively low tissue penetration by the antibody. Despite its primary action on B cells, the B cell depletion that resulted from treatment with rituximab was associated with a reduction in T cell memory and activation. Some NZB/W F1 mice appeared to be resistant to the B cell-depleting action of rituximab, which was attributed to a rapid clearance of circulating anti-CD20 antibodies and/or increased BAFF secretion<sup><a href="#ref-21">21</a></sup>.</p><p class="" id=d3524e850>Data from the LUNAR trial showed that rituximab, when added to standard induction immunosuppressive regimens, did not increase the rate of renal response, despite leading to more pronounced improvements in serological parameters and proteinuria<sup><a href="#ref-22">22</a></sup>. Proposed explanations for this apparent paradox include the efficacy of background immunosuppression, suboptimal depletion of tissue-infiltrating B cells and plasma cells, increased BAFF secretion, and inadequate sensitivity of clinical efficacy endpoints. Lack of treatment efficacy could also be related to monoclonal antibody metabolism, reduced antibody binding due to FcγRIII polymorphism, complement depletion, increased expression of complement inhibitory molecules such as CD55 and CD59, abnormal lipid raft composition, or limited access to the parenchyma of solid organs<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. In this regard, B cells are present in the tubulo-interstitium and contribute to local inflammation and kidney injury<sup><a href="#ref-25">25</a></sup>. It is currently unknown to what degree rituximab can directly deplete B cells in the kidney. Another mechanism for rituximab resistance may involve the upregulation of CD46, a key surface protein that inhibits complement activation. Serum CD46 level, possibly a product of proteolytic cleavage from apoptotic cell membranes, is increased in SLE patients with active disease compared to patients with inactive disease<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>. Whether combination therapy targeting both CD46 and CD20 may increase efficacy remains to be investigated. Despite the negative results in pivotal trials, rituximab is commonly used in the management of SLE patients, including patients with LN, in view of the favorable real-world clinical experience in severe renal or extra-renal manifestations and its relatively low toxicity, especially in patients who have an inadequate response to or who cannot tolerate standard therapies. Results from post-hoc analysis of the LUNAR trial also suggested that it may be particularly useful in high-risk patient groups such as Afro-Americans<sup><a href="#ref-28">28</a>–<a href="#ref-32">32</a></sup>.</p></div><div class=section><a name=d3524e883 class=n-a></a><h3 class=section-title>Obinutuzumab</h3><p class="" id=d3524e888>Obinutuzumab is a glycoengineered, type II, humanized anti-CD20 antibody developed to treat lymphoproliferative disorders and to alleviate several mechanisms which could lead to treatment resistance. Obinutuzumab has no fucosylated sugars on the Fc portion and demonstrates enhanced binding affinity to the FcγRIII receptor on immune effector cells<sup><a href="#ref-24">24</a></sup>. Obinutuzumab is more effective than rituximab in inducing direct B cell death and antibody-dependent cellular cytotoxicity and phagocytosis. Unlike rituximab, it does not relocalize CD20 to lipid rafts and its effect on B cell depletion is not influenced by complement protein exhaustion or complement-inhibiting factors<sup><a href="#ref-24">24</a></sup>. Pre-clinical data showed the superior efficacy of obinutuzumab in B cell depletion compared with rituximab<sup><a href="#ref-24">24</a></sup>. Recent results from the phase II NOBILITY study (NCT02550652) showed that obinutuzumab, when added to background immunosuppression comprising corticosteroids and mycophenolate, increased the rates of achieving primary and secondary efficacy endpoints, possibly related to a rapid and complete depletion of peripheral, memory, and naïve B cell subsets and plasmablasts<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>.</p></div><div class=section><a name=d3524e911 class=n-a></a><h3 class=section-title>Belimumab and agents that target the BAFF/APRIL pathway</h3><p class="" id=d3524e916>BAFF and a proliferation-inducing ligand (APRIL) are transmembrane proteins of the TNF family synthesized by myeloid cells. They can be proteolytically cleaved from the cell and exist in soluble form. BAFF and APRIL bind to receptors such as transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B-cell maturation antigen (BCMA). BAFF and APRIL are required for B cell survival from their initial development to terminal differentiation. BAFF promotes the survival and maturation of transitional B cells into mature B cells and supports B cell proliferation, plasma cell survival, and class-switch recombination. APRIL also promotes cell survival and class-switch recombination and plays an important role in T cell-independent responses<sup><a href="#ref-13">13</a></sup>. Inhibition of B cell survival factors represents an alternative approach to inhibit B cell and humoral immune responses. Belimumab is a human IgG1λ antibody that blocks the bioactivity of soluble BAFF, thus inhibiting B cell survival and differentiation. Results from two randomized controlled trials (RCTs), BLISS-52 and BLISS-76, demonstrated the efficacy of belimumab in active SLE patients, but patients with moderate or severe LN or neuropsychiatric complications were excluded from these trials<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a></sup>. Post-hoc analysis of the pooled data from these trials suggested an efficacy of belimumab treatment on renal manifestations and a decreased incidence of renal flare in patients who received belimumab<sup><a href="#ref-37">37</a></sup>. Whether the latter could be explained by sustained inhibition of memory B cells and plasma cells remains speculative<sup><a href="#ref-38">38</a></sup>. A phase III clinical trial which investigated the efficacy of belimumab in LN (BLISS-LN; NCT01639339) was completed recently, and the results showed that a higher number of patients met its primary and secondary endpoints when treated with belimumab plus standard induction therapy compared to placebo and standard induction therapy<sup><a href="#ref-39">39</a></sup>.</p><p class="" id=d3524e942>While data on belimumab in SLE and LN appear to be encouraging, other anti-BAFF therapies have failed to demonstrate efficacy in clinical trials. Results from the ILLUMINATE-1 and -2 trials showed that treatment with tabalumab, a monoclonal antibody against both soluble and membrane-bound BAFF, did not meet the primary efficacy endpoint of SLE responder index (SRI)-5 in patients with active SLE but no renal involvement<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>, and pooled data from these two RCTs did not suggest beneficial effects of tabalumab on the renal outcomes<sup><a href="#ref-42">42</a></sup>. Atacicept is a human recombinant fusion protein of TACI and the Fc portion of IgG1. The APRIL-LN trial (NCT00573157), which aimed to investigate the role of atacicept in the treatment of active LN, was terminated early because of severe infective complications associated with low serum Ig level in the first few treated patients<sup><a href="#ref-43">43</a></sup>. Telitacicept, also known as RC18, is a novel recombinant TACI-Fc fusion protein that targets and inhibits BLyS (aka BAFF) and APRIL and suppresses the development and survival of plasma cells and mature B cells. A recent phase IIb study (NCT02885610) demonstrated that telitacicept in combination with standard therapy met its primary endpoint in active SLE patients without nephritis<sup><a href="#ref-44">44</a></sup>. Sequential rituximab-belimumab treatment in patients with active LN is a therapeutic approach currently being investigated (CALIBRATE; NCT02260934), aiming to ensure adequate B cell suppression by first depletion and then preventing their repopulation using belimumab<sup><a href="#ref-45">45</a></sup>. Interim data from the CALIBRATE study showed that despite B cell depletion and delayed circulating B cell reconstitution, sequential rituximab-belimumab treatment did not improve clinical outcome<sup><a href="#ref-45">45</a></sup>. Results from the SynBioSe study (NCT02284984) demonstrated that combination treatment with rituximab and belimumab in SLE patients with severe and refractory disease improved clinical outcome, and this was associated with decreased production of neutrophil extracellular traps (NETs)<sup><a href="#ref-46">46</a></sup>. A phase II clinical trial (SynBioSe-2; NCT03747159) will investigate the efficacy of belimumab followed by rituximab in LN patients. A phase III clinical trial (BLISS-BELIEVE; NCT03312907) investigating the efficacy and safety of belimumab administered in combination with rituximab in patients with active SLE is ongoing<sup><a href="#ref-47">47</a></sup>. Another ongoing study (phase II; NCT04058028) is investigating the use of BAFF/inducible T-cell co-stimulator ligand (ICOSL) bispecific antibody in active SLE patients without recent cerebral or renal involvement.</p></div><div class=section><a name=d3524e983 class=n-a></a><h3 class=section-title>Other therapies targeting B cells or plasma cells</h3><p class="" id=d3524e988>B cell depletion can also be achieved by monoclonal antibodies binding to other B cell surface molecules such as CD19 (XmAb5871). In a recent phase II clinical trial (NCT02725515), XmAb5871 treatment of non-organ-threatening SLE patients did not meet the primary endpoint of “no loss of improvement (LOI)” but achieved the secondary endpoint of “time-to-LOI and safety”<sup><a href="#ref-48">48</a></sup>. Emerging evidence suggests that proteasome inhibitors such as bortezomib and ixazomib (an oral proteasome inhibitor with fewer neurological complications, such as a lower risk of peripheral neuropathy) can target plasma cells through binding to 26S proteasome and inhibiting its chymotrypsin-like activity and inactivating the nuclear factor kappa-light chain enhancer of activated B cell process. Preliminary clinical experience showed the efficacy of bortezomib in active LN patients who were refractory to conventional induction therapies<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>, although the high rates of treatment discontinuation due to poor drug tolerability remains a concern. Phase II clinical studies are currently underway to investigate the use of bortezomib in SLE patients (NCT02102594) and ixazomib in LN patients (NCT02176486). The MISSION study (NCT03393013) is a phase Ib/II trial that investigates the safety and tolerability of KZR-616, a specific immunoproteasome inhibitor, in patients with active SLE with or without LN (phase Ib) or patients with active proliferative LN (phase II). Results from the phase Ib study showed that KZR-616 at a dose of 45 mg SC was safe and well tolerated<sup><a href="#ref-51">51</a></sup>, and the phase II clinical trial is still ongoing.</p><p class="" id=d3524e1006>Aiolos and Ikaros are members of the Ikaros family of hemopoietic-specific zinc-finger transcription factors that play key roles in the regulation of lymphocyte development and differentiation<sup><a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>. Ikaros is expressed in pluripotent hemopoietic stem cells and regulates both lymphoid and myeloid cell development. Through its ability to regulate the development of plasmacytoid dendritic cells, Ikaros can also regulate key inflammatory pathways such as signal transducer and activator of transcription (STAT) 4 and IFN-α pathways<sup><a href="#ref-54">54</a></sup>. Aiolos contributes to B cell development and facilitates the generation of long-lived high-affinity bone marrow plasma cells. Aiolos is weakly expressed in pro-B cells and is increased in pre-B cells and mature peripheral B cells<sup><a href="#ref-55">55</a></sup>. Studies have shown that Aiolos expression is increased in peripheral blood mononuclear cells (PBMCs) from SLE patients compared to healthy subjects<sup><a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>. CC-220 (iberdomide) is a modulator of the cullin ring ligase 4-cereblon (CRL4<sup>CRBN</sup>) E3 ubiquitin ligase complex, which induces ubiquitination of the CRBN substrates Aiolos and Ikaros, resulting in their proteasomal degradation. <i>In vitro</i> studies demonstrated that the addition of iberdomide to B cells or PBMCs from SLE patients or healthy subjects, respectively, reduced Aiolos and Ikaros expression and inhibited BAFF-induced B cell differentiation and the production of anti-dsDNA antibodies and anti-phospholipid antibodies<sup><a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>. A phase IIa clinical study (NCT02185040), which investigated the tolerability and effect of iberdomide on skin, joint, and serological manifestations in SLE patients, reported that iberdomide significantly reduced B cell subset populations and plasmacytoid dendritic cells and improved arthritis and cutaneous lupus erythematosus disease area and severity index (CLASI) activity score, an assessment score for cutaneous involvement<sup><a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>. A phase IIb clinical study (NTC03161483) to investigate the efficacy and safety of iberdomide in a larger cohort of patients with active SLE is ongoing.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3524e1056>Emerging therapies targeting T lymphocytes</h2><p class="" id=d3524e1059>T lymphocytes in lupus patients exhibit a lower activation threshold compared with T cells in healthy subjects<sup><a href="#ref-60">60</a></sup>. T cell receptor (TCR)-mediated activation results in increased calcium influx and activation of calcineurin, a calcium–calmodulin-dependent serine-threonine phosphatase. Calcineurin activation leads to nuclear factor of activated T cells (NFAT) dephosphorylation, nuclear translocation of NFAT, and downstream induction of IFN-γ, TNF-α, and IL-2, IL-4, IL-6, and IL-17<sup><a href="#ref-61">61</a></sup>. Calcineurin inhibitors (CNIs) such as cyclosporine A (CsA), tacrolimus (TAC), or voclosporin inhibit the T-cell-mediated immune response by binding to cytosolic immunophilins such as cyclophilins or FK506-binding protein (FKBP12), then inhibit calcineurin activity and NFAT dephosphorylation<sup><a href="#ref-61">61</a></sup>. Triple immunosuppression that includes corticosteroids, CNIs, and mycophenolate is the standard-of-care immunosuppressive regimen to prevent kidney transplant rejection<sup><a href="#ref-62">62</a></sup>. The same approach has been used in animal studies and clinical practice in the management of SLE. Treatment of MRL/lpr mice with prednisolone, TAC, and mycophenolate showed increased efficacy compared with monotherapy, and transcriptomic analysis demonstrated synergistic actions of the different drugs targeting different disease-relevant pathogenic pathways<sup><a href="#ref-63">63</a></sup>. In addition to its action on T cells, CNIs modulate the podocyte cytoskeleton through synaptopodin-regulated Ras homolog family member A (RhoA) and Ras-related C3 botulinum toxin substrate 1 (Rac1), suppress the dephosphorylation and degradation of synaptopodin, and directly ameliorate the injury to podocyte foot process barrier function<sup><a href="#ref-64">64</a></sup>. Based on this dual action, CNIs are commonly used in the management of glomerular diseases characterized by persistent proteinuria<sup><a href="#ref-65">65</a></sup>. Compared with CsA, TAC is associated with less hirsutism and coarsening of facial features. Results from recent clinical trials showed that dual or triple (termed “multitarget” in some studies) immunosuppressive regimens that included TAC or CsA were associated with comparable or higher short-term response rates, and often more rapid reduction of proteinuria, in the treatment of patients with active severe LN compared to control groups treated with standard immunosuppressive regimens that did not include a CNI<sup><a href="#ref-66">66</a>–<a href="#ref-73">73</a></sup>. With the level of proteinuria being a key component in the definition of treatment response, the findings are not unanticipated. One should be reminded that proteinuria is but a surrogate biomarker, one that is relatively easy to measure repeatedly, for long-term renal survival<sup><a href="#ref-74">74</a></sup>, and that the preservation of long-term kidney function is the ultimate objective in LN management<sup><a href="#ref-75">75</a></sup>. An alternative approach to inclusion of a CNI upfront in the treatment of active nephritis is to add the drug in patients whose proteinuria has not decreased to an acceptable low level after treatment with standard therapies, and our group has reported on the efficacy and safety of long-term TAC treatment adopting this approach<sup><a href="#ref-76">76</a></sup>. Both CsA and TAC are associated with marked individual variations in pharmacokinetics and the side-effects of nephrotoxicity and hypertension, among others, and discontinuation after a relatively short duration of treatment is associated with a high rate of relapse in proteinuric kidney diseases<sup><a href="#ref-77">77</a>,<a href="#ref-78">78</a></sup>. Questions that need to be answered regarding the role of TAC or CsA in the management of LN include the optimal level and duration of drug exposure, how to avoid nephrotoxicity, especially in patients with significant chronic kidney disease, and their impact on long-term clinical outcomes.</p><p class="" id=d3524e1118>Voclosporin is a novel calcineurin inhibitor that is an analogue of CsA. Although voclosporin is structurally similar to CsA, a single carbon atom is added to the amino acid-1 region, resulting in enhanced binding to calcineurin and increased potency, faster elimination, and less plasma variation than CsA<sup><a href="#ref-79">79</a>–<a href="#ref-81">81</a></sup>. In a recent phase II clinical trial in active LN (AURA-LV; NCT02141672), voclosporin (high or low dose) when combined with corticosteroids and mycophenolate mofetil (MMF) showed superior renal response rates compared with corticosteroids and MMF induction at 24 weeks and 48 weeks<sup><a href="#ref-82">82</a></sup>. A subsequent phase III study (AURORA; NCT03021499) showed that voclosporin (23.7 mg bid) in combination with MMF and corticosteroids, the latter adopting a force-tapering reduced-dose regimen, achieved statistically superior and faster renal response rate (defined as a urinary protein-to-creatinine ratio [UPCR] of ≤0.5 mg/mg and an estimated glomerular filtration rate [eGFR] of ≥60 ml/minute or no decrease from baseline of &gt;20%), compared with MMF and corticosteroid treatment<sup><a href="#ref-83">83</a></sup>. It is prudent to avoid over-immunosuppression in patients treated with triple immunosuppression, as suggested by the higher rate of infective complications in Chinese patients treated with the “multitarget” regimen<sup><a href="#ref-67">67</a></sup> and the significant number of infection-related deaths in Asian patients in the AURA-LV trial<sup><a href="#ref-82">82</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3524e1147>Emerging therapies targeting co-stimulatory pathways</h2><p class="" id=d3524e1150>Co-stimulation in T lymphocyte activation also plays an important role in autoimmunity. Co-stimulation requires accessory molecules such as CD28/CD80/CD86 and CD40/CD40L. The engagement of CD28 on the cell surface of naïve T cells by CD80 and CD86 present on antigen-presenting cells or B cells activates signaling pathways that promote clonal expansion, T cell survival, and release of pro-inflammatory cytokines and other mediators of inflammation<sup><a href="#ref-84">84</a></sup>. Once activated, T cells express cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a co-stimulatory molecule homologous to CD28, which has a higher affinity to CD80 and CD86. CTLA4 serves as a negative regulator of T and B cell co-stimulation and terminates T cell response and cytokine secretion. CTLA4 serves as a master switch for peripheral T cell tolerance as demonstrated by massive lymphoproliferation and early death in CTLA4-knockout mice<sup><a href="#ref-85">85</a></sup>.</p><p class="" id=d3524e1161>Abatacept (or CTLA4Ig) is a soluble fusion protein comprising the extracellular domain of CTLA4 and a modified fragment of the Fc domain of human IgG. It is a CTLA4 agonist that interrupts the interaction of CD80/CD86 with CD28 and thus inhibits T cell co-stimulation, thereby suppressing T cell activation and B cell response<sup><a href="#ref-86">86</a></sup>. Treatment of mice with CTLA4Ig reduced the expansion of IgG and IgM autoreactive B cell subsets and CD4<sup>+</sup> T cells and suppressed Ig subclass switching, delayed disease onset and anti-dsDNA production, decreased the severity of proteinuria and renal damage, and prolonged survival<sup><a href="#ref-84">84</a></sup>. Combination treatment with CTLA4Ig and cyclophosphamide was more effective than CTLA4Ig alone in delaying the onset of nephritis in mice and was effective in reducing renal damage in mice with advance renal disease<sup><a href="#ref-87">87</a></sup>. A phase II clinical trial (NCT00430677) showed that induction therapy with abatacept combined with corticosteroids and MMF improved proteinuria and serological parameters in patients with active proliferative LN after 12 months but failed to meet the superiority efficacy endpoint (time to complete renal response)<sup><a href="#ref-88">88</a></sup>. Results from a phase III study (ALLURE; NCT01714817) showed that, in patients with active LN, treatment with abatacept on a background of corticosteroids and MMF for 2 years with a blinded long-term extension improved serological parameters with a more rapid improvement in proteinuria compared with controls who received corticosteroids and MMF with placebo, but the primary endpoint of demonstrating a higher complete remission rate based on clinical parameters in the abatacept group was not achieved<sup><a href="#ref-89">89</a></sup>. The negative results in both studies have been attributed to the relatively high efficacy of background induction treatment and perhaps over-stringent criteria for treatment response<sup><a href="#ref-90">90</a></sup>. It has been reported that the podocytes in patients and mice with proteinuric kidney diseases showed increased CD80 expression, which was associated with down-regulation of β1 integrin<sup><a href="#ref-91">91</a>,<a href="#ref-92">92</a></sup>. Therefore, apart from interrupting the interaction of CD80/CD86 with CD28, abatacept may stabilize podocyte cytoskeleton and reduce proteinuria through its effect on β1-integrin<sup><a href="#ref-92">92</a></sup>. Whether abatacept may be better suited to treat LN patients with increased CD80 expression in podocytes has not been investigated.</p><p class="" id=d3524e1203>Blockade of the CD40/CD40L pathway presents an alternative therapeutic approach targeting co-stimulatory signals in T lymphocytes. A phase II clinical trial (NCT02770170) is underway to investigate the efficacy and safety of BI655064 (humanized anti-CD40 monoclonal antibody) in combination with standard-of-care therapy in active LN patients. Another phase II clinical trial (NCT03610516) will test the role of CFZ533 (a humanized anti-CD40 monoclonal antibody) in LN patients who show persistent significant proteinuria after standard induction treatments. Data from a recent phase II study (NCT02804763) demonstrated that dapirolizumab pegol (a pegylated Fab anti-CD40L) treatment in active SLE patients was associated with numerically higher response rates and greater improvement in several clinical outcome measures compared with placebo, but the difference in primary efficacy endpoint of British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response between the two groups did not reach statistical significance<sup><a href="#ref-93">93</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3524e1214>Emerging therapies targeting signaling pathways, pro-inflammatory cytokines, complement activation, or neutrophil extracellular traps</h2><p class="" id=d3524e1217>In SLE, multiple signaling pathways and inflammatory mediators are induced by cells of the innate and adaptive immune system and contribute to both systemic and local inflammation. Increases in type I IFN signature, which promotes B cell differentiation and loss of tolerance, and IL-17 and IL-23, which drive tissue injury, are prominent examples<sup><a href="#ref-94">94</a></sup>.</p><div class=section><a name=d3524e1224 class=n-a></a><h3 class=section-title>Mammalian or mechanistic target of rapamycin</h3><p class="" id=d3524e1229>The mammalian or mechanistic target of rapamycin (mTOR) is an evolutionarily conserved serine-threonine kinase that plays a key role in the regulation of cell proliferation, metabolism, and survival. Increased mTOR activation is observed in patients and mice with LN<sup><a href="#ref-95">95</a></sup>. Sirolimus is a naturally occurring macrolide antibiotic produced by <i>Streptomyces hygroscopicus</i> and is a specific inhibitor of the mTOR pathway. It is a potent inhibitor of B and T cell proliferation. In pre-nephritic NZB/W F1 mice, treatment with sirolimus suppressed lymphoproliferation, reduced monocyte chemoattractant protein-1 (MCP-1) expression in the kidney, and delayed phenotypic manifestation of disease<sup><a href="#ref-96">96</a></sup>. Sirolimus treatment given after the onset of nephritis in NZB/W F1 mice was effective in decreasing anti-dsDNA level, improving kidney histopathology, and prolonging survival<sup><a href="#ref-97">97</a>–<a href="#ref-99">99</a></sup>. There is also emerging evidence that the anti-proliferative property of mTOR inhibitors extends beyond lymphocytes to non-immune cells. We recently demonstrated that sirolimus decreased mesangial cell proliferation and their binding by anti-dsDNA antibodies and suppressed fibrotic responses in mesangial cells when cells were exposed to anti-dsDNA antibodies or transforming growth factor (TGF)-β1, and the effect was mediated through down-regulation of mTOR and extracellular signal-regulated kinase phosphorylation<sup><a href="#ref-95">95</a></sup>. In NZB/W F1 mice with active nephritis, sirolimus was as effective as mycophenolate in attenuating kidney inflammation and fibrosis<sup><a href="#ref-95">95</a></sup>. A recent single-arm phase I/II study (NCT00779194) reported that sirolimus treatment in patients with active SLE but without nephritis or life-threatening lupus complications resulted in a decrease in disease activity score and a T cell profile indicating a less pro-inflammatory phenotype<sup><a href="#ref-100">100</a></sup>. We have also reported our experience of the use of sirolimus in LN patients, suggesting that this group of drugs may have a role in LN management, especially in patients who do not tolerate other treatments or who could derive benefit from the unique properties of these drugs, such as a lower rate of malignancies<sup><a href="#ref-101">101</a>,<a href="#ref-102">102</a></sup>.</p></div><div class=section><a name=d3524e1271 class=n-a></a><h3 class=section-title>Janus kinase-1, tyrosine kinase-2, and Bruton’s tyrosine kinase signaling pathways</h3><p class="" id=d3524e1276>The success of Janus kinase (JAK) inhibition in murine lupus has prompted clinical trials on JAK inhibitors in human SLE. One phase II RCT (NCT02708095) demonstrated the efficacy of baricitinib (a JAK1/2 inhibitor) in alleviating arthritis in SLE patients<sup><a href="#ref-103">103</a></sup>. A phase IIb study (PF-06700841) will investigate a selective JAK1 inhibitor in moderate-to-severe active SLE patients without renal or cerebral involvement who show an inadequate response to standard therapies. Inhibition of JAK1 should be used with caution, as a phase II clinical trial on solcitinib (a selective JAK1 inhibitor) (NCT01777256) was discontinued because of severe drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and hepatic function abnormalities<sup><a href="#ref-104">104</a>,<a href="#ref-105">105</a></sup>. Tyrosine kinase 2 (TYK2) is a member of the JAK family and functions downstream of IL-12, IL-23, and type I IFN signaling. A phase II RCT (PAISLEY; NCT03252587) will evaluate the safety and efficacy of BMS-986165, a specific TYK2 inhibitor, in active SLE patients with joint and/or skin involvement<sup><a href="#ref-106">106</a></sup>, and patients who successfully complete the protocol-required treatment period will be recruited to a subsequent phase II trial that will investigate the long-term safety and efficacy (NCT03920267). Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase expressed in B cells and myeloid cells, and it plays an important role in B cell development, survival, and activation and mediates TLR signaling in macrophages. Inhibition of BTK in lupus-prone mice after disease onset reduced total splenic B cell number and suppressed B cell activation, accompanied by decreased proteinuria and improvement of serological parameters<sup><a href="#ref-107">107</a></sup>. Treatment of moderate-to-severe active SLE patients without cerebral or renal involvement with the BTK inhibitor fenebrutinib reduced CD19<sup>+</sup> B cells, anti-dsDNA antibody titer, and BTK-dependent signature in plasmablasts, but the primary clinical efficacy endpoint (SRI-4) was not met<sup><a href="#ref-108">108</a></sup>.</p></div><div class=section><a name=d3524e1307 class=n-a></a><h3 class=section-title>Cytokines</h3><p class="" id=d3524e1312>The importance of type I IFN in SLE and LN is well established. Anifrolumab is a monoclonal antibody against type I IFN receptor subunit 1, and the results from a phase IIb clinical trial (MUSE) showed that anifrolumab treatment significantly suppressed type I IFN gene signatures and lupus disease activity<sup><a href="#ref-109">109</a></sup>. The results from two subsequent phase III RCTs (TULIP-1 and -2) also showed the clinical benefits of anifrolumab in moderate-to-severe active SLE patients. Although the primary endpoint (SRI-4) was not achieved in TULIP-1, anifrolumab treatment could facilitate corticosteroid reduction and improve disease activity scores such as the CLASI and BICLA scores<sup><a href="#ref-110">110</a></sup>. The results from TULIP-2 corroborated with TULIP-1: anifrolumab met its primary endpoint (BICLA scores at 52 weeks) in active SLE patients<sup><a href="#ref-111">111</a></sup>. Consistent with the scientific rationale, the clinical benefit of anifrolumab appears to be more evident in patients with high type I IFN signatures<sup><a href="#ref-111">111</a></sup>.</p><p class="" id=d3524e1331>Given the pathogenic significance of the IL-17/IL-23 axis in SLE and LN, inhibition of these cytokines may potentially ameliorate SLE and LN. Secukinumab is a fully humanized IgG1κ monoclonal anti-IL-17A antibody and is an approved treatment for active psoriatic arthritis and ankylosing spondylitis, and a phase II clinical trial is underway to investigate its role in patients with refractory LN (NCT04181762). Guselkumab is an anti-IL-23 monoclonal antibody licensed for the treatment of plaque psoriasis, and its use in LN will be explored in a forthcoming phase II study. IL-2 regulates CD4<sup>+</sup> T cell development and survival, and defective IL-2 production leads to dysregulation in the immune system in SLE patients<sup><a href="#ref-112">112</a>,<a href="#ref-113">113</a></sup>. Previous clinical trials demonstrated that treatment of SLE patients with low-dose IL-2 promoted regulatory T (Treg) cells and inhibited T<sub>H</sub>17 cells and was associated with the induction of remission<sup><a href="#ref-114">114</a>,<a href="#ref-115">115</a></sup>. One recent RCT showed that low-dose IL-2 treatment (1 million IU subcutaneously every other day for 2 weeks) in active SLE patients did not meet the primary efficacy endpoint of SRI-4 at 12 weeks but achieved higher remission rates than placebo in patients with LN and was well tolerated<sup><a href="#ref-116">116</a></sup>. The low-dose IL-2 group also showed expansion of Treg and natural killer cells<sup><a href="#ref-116">116</a></sup>.</p></div><div class=section><a name=d3524e1365 class=n-a></a><h3 class=section-title>Complement cascade</h3><p class="" id=d3524e1370>The complement cascade plays an essential role in innate immunity and comprises more than 30 circulating proteins. The complement system can be activated through one of three initiation pathways, namely the classical pathway, mannose-binding lectin pathway, and the alternative pathway<sup><a href="#ref-117">117</a></sup>. The three pathways converge at C3, resulting in the cleavage of C3 to the activated components C3a and C3b. Dysregulation of complement activation is observed in patients and mice with LN. In LN, deposition of C3-containing immune complexes in the glomeruli initiates tissue injury, whereas deficiencies of some of the components of the classical complement pathway, such as C1q and C4, are associated with an increase in the incidence of lupus in humans and also lupus-like disease in C1q or C4 knockout mice<sup><a href="#ref-118">118</a></sup>. APL-2 (pegcetacoplan) is a small, synthetic cyclic peptide that binds and inhibits C3 and C3b and interferes with the formation of C3 and C5 convertases as well as inhibits the activity of pre-formed C3 and C5 convertases<sup><a href="#ref-119">119</a></sup>. A phase II clinical trial investigated the safety and efficacy of daily APL-2 subcutaneous infusion, administered for 16 weeks with a 6-month safety follow-up, in patients with various glomerulopathies including LN (DISCOVERY; NCT03453619). Preliminary experience from two LN patients recruited into this trial suggests that APL-2 is well-tolerated and treatment was associated with a reduction of proteinuria<sup><a href="#ref-120">120</a></sup>. Yet the pharmaceutical company has decided to stop the development program for APL-2 in LN after completion of the phase II trial and prefers to focus on other diseases<sup><a href="#ref-121">121</a></sup>.</p><p class="" id=d3524e1393>Treatment of pre-nephritic NZB/W F1 mice with a monoclonal antibody that inhibits C5 cleavage to the potent pro-inflammatory and pro-thrombotic molecules C5a and C5b-9 delayed the development of proteinuria, decreased anti-dsDNA antibody level, improved kidney histopathology, and prolonged survival<sup><a href="#ref-122">122</a></sup>. Eculizumab is a recombinant fully humanized hybrid IgG2/IgG4 monoclonal antibody that directly binds human complement component C5 and prevents its cleavage to C5a and C5b-9, thereby blocking terminal complement activation while preserving the functions of early complement components. The success of inhibiting C5 cleavage in murine lupus has prompted a single-dose placebo-controlled phase I study to investigate the safety, pharmacodynamics, and pharmacokinetics of eculizumab in 24 SLE patients. While eculizumab at 4 or 8 mg/kg was well tolerated and complement level was reduced to baseline level 2 weeks after commencement of the study, clinical parameters were similar to the placebo group. Relatively low baseline disease activity was proposed as a possible reason for the lack of apparent clinical efficacy associated with eculizumab treatment<sup><a href="#ref-123">123</a>,<a href="#ref-124">124</a></sup>. A multicenter phase II clinical trial was designed to investigate the effect of eculizumab in patients with proliferative LN, but the study encountered logistic delays and was terminated<sup><a href="#ref-125">125</a></sup>. Eculizumab has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit C5-mediated thrombotic microangiopathy<sup><a href="#ref-126">126</a></sup>. Eculizumab has been reported to be effective in the treatment of a patient with catastrophic antiphospholipid antibody syndrome<sup><a href="#ref-127">127</a></sup> and also in a patient with refractory LN<sup><a href="#ref-128">128</a></sup>. It has been proposed that eculizumab may be beneficial in the treatment of LN patients who have a thrombotic component analogous to aHUS, evidence of C5-driven glomerular inflammation, or antiphospholipid syndrome, although further studies are warranted. It is noteworthy that inhibition of complement activation at the level of C5 is associated with <i>Neisseria</i> infection and prophylactic measures may be required<sup><a href="#ref-118">118</a></sup>.</p><p class="" id=d3524e1431>Dysregulation of the classical complement pathway contributes to the pathogenesis of SLE, and there is emerging evidence to show that the alternative pathway also plays a significant role. The alternative pathway is triggered by the activation of factor B, a trypsin-like serine protease that is the proteolytically active component of C3 and C5 convertases. Factor B serves as an acute-phase protein and also as a B cell growth factor. Data from 222 Chinese patients with LN showed reduced plasma C1q and C3 levels and increased levels of factor B, C3a, C5a, and soluble C5b-9<sup><a href="#ref-129">129</a></sup>. Plasma factor B level correlated with that of C5a and soluble C5b-9, and factor B colocalized with C3b and C5b-9 deposits in the glomeruli<sup><a href="#ref-129">129</a></sup>. MRL/lpr mice deficient in factor B showed reduced proteinuria, fewer active serological parameters, and improved kidney histology and vasculitis features compared to wild-type and heterozygous mice<sup><a href="#ref-130">130</a></sup>. The association between factor B deficiency and improved disease manifestation may be attributed to decreased C3 activation and/or B cell development. These data suggest that factor B may present a novel therapeutic target in LN<sup><a href="#ref-130">130</a></sup>. A highly potent, reversible, and selective small molecule factor B inhibitor (LNP023) is available<sup><a href="#ref-131">131</a>,<a href="#ref-132">132</a></sup>. Oral administration of LNP023 to mice with KRN-induced arthritis reduced overall clinical score and inhibited complement activation and infiltration of immune cells in the joints<sup><a href="#ref-131">131</a></sup>. In a rodent model of membranous nephropathy, LNP023 administration before disease onset suppressed the development of proteinuria, while treatment after disease onset delayed progression and attenuated glomerulopathy<sup><a href="#ref-131">131</a></sup>. Phase II clinical studies will investigate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (NCT03439839 and NCT03896152) and IgA nephropathy (NCT03373461).</p><p class="" id=d3524e1466>OMS721 (narsoplimab) is a human monoclonal antibody that targets mannan-binding lectin serine protease 2 (MASP-2), the effector enzyme of the lectin pathway. A phase II study is ongoing to investigate the safety of OMS721 in patients with glomerular diseases including active LN and will look into its potential steroid-sparing effect (NCT02682407). Preliminary results appear encouraging, with treated patients showing a significant reduction of proteinuria (mean reduction 69%) and the feasibility for steroid tapering<sup><a href="#ref-133">133</a></sup>. A phase III study will investigate the effect of OMS721 in LN patients<sup><a href="#ref-134">134</a></sup>.</p></div><div class=section><a name=d3524e1478 class=n-a></a><h3 class=section-title>Neutrophil extracellular traps</h3><p class="" id=d3524e1483>Neutrophils play a critical role in the innate immune response, and they also regulate the adaptive immune response<sup><a href="#ref-135">135</a></sup>. Neutrophil cell death, termed NETosis, results in the formation of NETs, which are composed of nuclear components such as DNA and histones decorated with proteins from primary, secondary, and tertiary granules such as myeloperoxidase, neutrophil elastase, pentraxin 3, and matrix metalloproteinase 9. Under physiological conditions, neutrophils release NETs as a defense mechanism to trap and kill microorganisms<sup><a href="#ref-135">135</a></sup>. NET formation can also be induced by sterile stimuli such as pro-inflammatory cytokines, immune complexes, or autoantibodies<sup><a href="#ref-135">135</a>,<a href="#ref-136">136</a></sup>. In SLE, NET formation is dysregulated and can be induced by ribonucleoprotein antibodies through FcγRIIB (also known as CD32) binding, by the antimicrobial peptide LL37, and by IFN-α produced by plasmacytoid dendritic cells<sup><a href="#ref-137">137</a></sup>. SLE-induced NETs are believed to be highly immunogenic and contain oxidized mitochondrial DNA, HMGB1, LL37, and immunostimulatory molecules<sup><a href="#ref-137">137</a>,<a href="#ref-138">138</a></sup>. The degradation and clearance of NETs in SLE patients are dependent on DNase 1, but DNase 1 activity is impaired in lupus because of the presence of either DNase 1 inhibitors or anti-NET antibodies that inhibit the access of DNase 1 to the NETs, and components of the increased NETs then trigger downstream tissue injury and inflammation<sup><a href="#ref-135">135</a>,<a href="#ref-139">139</a>,<a href="#ref-140">140</a></sup>. The inability to degrade NETs is associated with a higher propensity for LN<sup><a href="#ref-140">140</a></sup>. In lupus-prone mice, inhibition of NET formation using Cl-amidine (a chemical inhibitor of peptidylarginine deiminase-4)<sup><a href="#ref-141">141</a></sup>, DNase 1<sup><a href="#ref-142">142</a></sup>, or FR139317 (a specific endothelin-A receptor antagonist)<sup><a href="#ref-143">143</a></sup> resulted in delayed onset of disease, decreased proteinuria, and reduced deposition of immune complexes in the glomeruli as well as down-regulation of IFN-signature inflammatory responses in the bone marrow and kidney<sup><a href="#ref-141">141</a>–<a href="#ref-143">143</a></sup>, suggesting that targeting NETs may be beneficial to lupus patients. Tofacitinib, a JAK/STAT inhibitor, has been shown to reduce NET formation in lupus-prone mice, and this was associated with improvements in proteinuria and serological parameters<sup><a href="#ref-144">144</a></sup>. An ongoing phase I study is investigating the safety of tofacitinib in patients with SLE (NCT02535689). Combination therapy with rituximab and belimumab has also been shown to decrease immune complex-induced NET formation in SLE patients<sup><a href="#ref-46">46</a></sup>. Metformin has been shown to reduce NET formation in neutrophils stimulated with phorbol 12-myristate 13-acetate and decreased IFN-α secretion in plasmacytoid dendritic cells stimulated with mitochondrial DNA<sup><a href="#ref-145">145</a></sup>. Data from a study in Chinese patients (ChiCTR-TRC-12002419) showed that metformin added to conventional treatment for 12 months in SLE patients with mild-to-moderate disease resulted in a decrease in SLE disease activity index (SLEDAI) score by over 50%<sup><a href="#ref-145">145</a></sup>. Mitochondrial DNA is deposited in NETs in renal biopsy specimens from LN patients, and mitochondrial DNA has been shown to induce higher levels of IFN-α in plasmacytoid dendritic cells compared with anti-dsDNA antibodies. In the MUSE trial, SLE patients with a high type I IFN signature showed higher plasma levels of neutrophil granule constituents such as myeloperoxidase, human neutrophil elastase, and citrullinated histone H3 levels, and treatment with anifrolumab for 1 year resulted in a significant decrease in circulating neutrophil NET complexes compared to the placebo group<sup><a href="#ref-146">146</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3524e1571>Conclusion and future direction</h2><p class="" id=d3524e1574>As a direct result of greater understanding of disease pathogenesis and key pathways and molecules causing immune activation or organ injury, the development and implementation of novel therapeutic agents for SLE and LN have grown substantially over the past decade. Yet, despite encouraging results from animal studies, relatively few novel therapies have successfully progressed to general clinical usage. Valuable lessons have been learnt from the clinical trials of these novel therapies. Indeed, many of these studies, including those which have apparently failed to achieve their intended aim of demonstrating superiority of the new drug compared with placebo, have provided clinical evidence that substantiate the scientific rationale supporting the clinical relevance of specific pathogenic pathways. Results from these trials, both the positive and the negative ones, have highlighted the heterogeneity in treatment response between different patient subgroups and the caveats and pitfalls in the design of clinical trials, resulting in improved trial design and therapeutic strategies. A challenge in the use of agents that target specific signaling pathways or cytokines is that some of the molecules could serve both pro-inflammatory and anti-inflammatory properties depending on the local cytokine milieu. Given that a multitude of effector mechanisms are activated during active disease, therapies that combine or target multiple pathways may be relevant, although the risk of over-immunosuppression could be a concern. Future trials should also explore ways of incorporating the new treatments to reduce the exposure to established but toxic therapies, especially corticosteroids.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3524e1580>Abbreviations</h2><p class="" id=d3524e1583>aHUS, atypical hemolytic uremic syndrome; APRIL, a proliferating-inducing ligand; BAFF, B cell activating factor; BICLA, British Isles lupus assessment group-based composite lupus assessment; BTK, Bruton’s tyrosine kinase; CLASI, cutaneous lupus erythematosus disease area and severity index; CNI, calcineurin inhibitor; CRBN, cereblon; CsA, cyclosporine A; CTLA4; cytotoxic T-lymphocyte-associated protein 4; ds, double-stranded; IFN, interferon; Ig, immunoglobulin; JAK, Janus kinase; IL, interleukin; LOI, loss of improvement; LN, lupus nephritis; MMF, mycophenolate mofetil; mTOR, mammalian or mechanistic target of rapamycin; NETs, neutrophil extracellular traps; NFAT; nuclear factor of activated T cells; NZB/W F1, New Zealand black and white, first generation; PBMC, peripheral blood mononuclear cell; RCT, randomized controlled trial; SLE, systemic lupus erythematosus; SRI, systemic lupus erythematosus responder index; STAT, signal transducer and activator of transcription; TAC, tacrolimus; TACI, transmembrane activator and cyclophilin ligand interactor; TLR, Toll-like receptor; TNF, tumor necrosis factor; Treg, regulatory T; TYK2, tyrosine kinase-2.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3524e1589>List of clinical studies and their acronyms</h2><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3></h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d3524e1594 class=n-a></a><tbody><a name=d3524e1596 class=n-a></a><tr><a name=d3524e1598 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1599 class=n-a></a>ALLURE: </td><td colspan=1 rowspan=1><a name=d3524e1602 class=n-a></a>“Efficacy and Safety Study of Abatacept to<br class=br>Treat Lupus Nephritis” Trial [NCT00430677]<sup><a href="#ref-89">89</a></sup></td></tr><tr><a name=d3524e1610 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1611 class=n-a></a>APRIL-LN: </td><td colspan=1 rowspan=1><a name=d3524e1614 class=n-a></a>“The Efficacy and Safety of Atacicept in<br class=br>Combination with Mycophenolate Mofetil Used<br class=br>to Treat Lupus Nephritis” Trial [NCT00573157]<sup><a href="#ref-43">43</a></sup></td></tr><tr><a name=d3524e1624 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1625 class=n-a></a>AURA-LV: </td><td colspan=1 rowspan=1><a name=d3524e1628 class=n-a></a>“Aurinia Urinary Protein Reduction Active - <br class=br>Lupus with Voclosporin” Trial [NCT02141672]<sup><a href="#ref-82">82</a></sup></td></tr><tr><a name=d3524e1636 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1637 class=n-a></a>AURORA: </td><td colspan=1 rowspan=1><a name=d3524e1640 class=n-a></a>“Aurinia Renal Response in Active Lupus with<br class=br>Voclosporin” Trial [NCT03021499]<sup><a href="#ref-83">83</a></sup></td></tr><tr><a name=d3524e1648 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1649 class=n-a></a>BLISS-52: </td><td colspan=1 rowspan=1><a name=d3524e1652 class=n-a></a>“A Study of Belimumab in Subjects with<br class=br>Systemic Lupus Erythematosus (SLE)” Trial<br class=br>[NCT00424476]<sup><a href="#ref-35">35</a></sup></td></tr><tr><a name=d3524e1663 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1664 class=n-a></a>BLISS-76: </td><td colspan=1 rowspan=1><a name=d3524e1667 class=n-a></a>“A Study of Belimumab in Subjects with<br class=br>Systemic Lupus Erythematosus (SLE)” Trial<br class=br>[NCT00410384]<sup><a href="#ref-36">36</a></sup></td></tr><tr><a name=d3524e1677 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1678 class=n-a></a>BLISS-BELIEVE: </td><td colspan=1 rowspan=1><a name=d3524e1681 class=n-a></a>“A Study to Evaluate the Efficacy and Safety<br class=br>of Belimumab Administered in Combination<br class=br>with Rituximab to Adult Subjects with Systemic<br class=br>Lupus Erythematosus (SLE) - BLISS-BELIEVE”<br class=br>Trial [NCT03312907]<sup><a href="#ref-47">47</a></sup></td></tr><tr><a name=d3524e1695 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1696 class=n-a></a>BLISS-LN: </td><td colspan=1 rowspan=1><a name=d3524e1699 class=n-a></a>“Efficacy and Safety of Belimumab in Patients<br class=br>with Active Lupus Nephritis (BLISS-LN)” Trial<br class=br>[NCT01639339]<sup><a href="#ref-39">39</a></sup></td></tr><tr><a name=d3524e1709 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1710 class=n-a></a>CALIBRATE: </td><td colspan=1 rowspan=1><a name=d3524e1713 class=n-a></a>“Rituximab and Belimumab for Lupus<br class=br>Nephritis” Trial [NCT02260934]<sup><a href="#ref-45">45</a></sup></td></tr><tr><a name=d3524e1721 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1722 class=n-a></a>ILLUMINATE-1: </td><td colspan=1 rowspan=1><a name=d3524e1725 class=n-a></a>“A Study of LY2127399 in Participants<br class=br>with Systemic Lupus Erythematosus” Trial<br class=br>[NCT01205438]<sup><a href="#ref-40">40</a></sup></td></tr><tr><a name=d3524e1735 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1736 class=n-a></a>ILLUMINATE-2: </td><td colspan=1 rowspan=1><a name=d3524e1739 class=n-a></a>“A Study of LY2127399 in Participants<br class=br>with Systemic Lupus Erythematosus” Trial<br class=br>[NCT01196091]<sup><a href="#ref-41">41</a></sup></td></tr><tr><a name=d3524e1750 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1751 class=n-a></a>LUNAR: </td><td colspan=1 rowspan=1><a name=d3524e1754 class=n-a></a>“A Study to Evaluate the Efficacy and Safety<br class=br>of Rituximab in Subjects with International<br class=br>Society of Nephrology/Renal Pathology Society<br class=br>(ISN/RPS) 2003 Class III or IV Lupus Nephritis”<br class=br>Trial [NCT00282347]<sup><a href="#ref-22">22</a></sup></td></tr><tr><a name=d3524e1768 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1769 class=n-a></a>MISSION: </td><td colspan=1 rowspan=1><a name=d3524e1772 class=n-a></a>“A Study of KZR-616 in Patients with Systemic<br class=br>Lupus Erythematosus With and Without<br class=br>Nephritis” Trial [NCT03393013]<sup><a href="#ref-51">51</a></sup></td></tr><tr><a name=d3524e1782 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1783 class=n-a></a>MUSE: </td><td colspan=1 rowspan=1><a name=d3524e1786 class=n-a></a>“A Study of the Efficacy and Safety of MEDI-<br class=br>546 in Systemic Lupus Erythematosus” Trial<br class=br>[NCT01438489]<sup><a href="#ref-109">109</a></sup></td></tr><tr><a name=d3524e1796 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1797 class=n-a></a>NOBILITY: </td><td colspan=1 rowspan=1><a name=d3524e1800 class=n-a></a>“A Study to Evaluate the Safety and Efficacy<br class=br>of Obinutuzumab Compared with Placebo in<br class=br>Participants with Lupus Nephritis (LN)” Trial<br class=br>[NCT02550652]<sup><a href="#ref-33">33</a></sup></td></tr><tr><a name=d3524e1812 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1813 class=n-a></a>PAISLEY: </td><td colspan=1 rowspan=1><a name=d3524e1816 class=n-a></a>“An Investigational Study to Evaluate BMS-<br class=br>986165 in Patients with Systemic Lupus<br class=br>Erythematosus” Trial [NCT03252587]<sup><a href="#ref-106">106</a></sup></td></tr><tr><a name=d3524e1826 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1827 class=n-a></a>SynBioSe-1: </td><td colspan=1 rowspan=1><a name=d3524e1830 class=n-a></a>“Synergetic B-cell Immunomodulation in SLE”<br class=br>Trial [NCT02284984]46</td></tr><tr><a name=d3524e1836 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1837 class=n-a></a>SynBioSe-2:</td><td colspan=1 rowspan=1><a name=d3524e1840 class=n-a></a>“Synergetic B-cell Immunomodulation in SLE<br class=br> - 2<sup>nd</sup> Study” Trial [NCT03747159]</td></tr><tr><a name=d3524e1848 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1849 class=n-a></a>TULIP-1:</td><td colspan=1 rowspan=1><a name=d3524e1852 class=n-a></a>“Efficacy and Safety of Anifrolumab Compared<br class=br>to Placebo in Adult Subjects with Active<br class=br>Systemic Lupus Erythematosus” Trial<br class=br>[NCT02446899]<sup><a href="#ref-110">110</a>,<a href="#ref-111">111</a></sup></td></tr><tr><a name=d3524e1867 class=n-a></a><td colspan=1 rowspan=1><a name=d3524e1868 class=n-a></a>TULIP-2:</td><td colspan=1 rowspan=1><a name=d3524e1871 class=n-a></a>“Efficacy and Safety of Two Doses of<br class=br>Anifrolumab Compared to Placebo in<br class=br>Adult Subjects with Active Systemic Lupus<br class=br>Erythematosus” Trial [NCT02446912]</td></tr></tbody></table></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d3524e1887 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d4406>References</h2><div class="section ref-list"><a name=d3524e1887 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d3524e1894 class=n-a></a>Cameron JS: Lupus nephritis. <i>J Am Soc Nephrol.</i> 1999; <b>10</b>(2): 413–24. <a target=xrefwindow id=d3524e1902 href="http://www.ncbi.nlm.nih.gov/pubmed/10215343">PubMed Abstract </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d3524e1911 class=n-a></a>Mohan C, Putterman C: Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. <i>Nat Rev Nephrol.</i> 2015; <b>11</b>(6): 329–41. <a target=xrefwindow id=d3524e1919 href="http://www.ncbi.nlm.nih.gov/pubmed/25825084">PubMed Abstract </a> | <a target=xrefwindow id=d3524e1922 href="https://doi.org/10.1038/nrneph.2015.33">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d3524e1931 class=n-a></a>Chan TM: Treatment of severe lupus nephritis: The new horizon. <i>Nat Rev Nephrol.</i> 2015; <b>11</b>(1): 46–61. <a target=xrefwindow id=d3524e1939 href="http://www.ncbi.nlm.nih.gov/pubmed/25421826">PubMed Abstract </a> | <a target=xrefwindow id=d3524e1942 href="https://doi.org/10.1038/nrneph.2014.215">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d3524e1951 class=n-a></a>Cooper GS, Dooley MA, Treadwell EL, <i> et al.</i>: Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. <i>Arthritis Rheum.</i> 1998; <b>41</b>(10): 1714–24. <a target=xrefwindow id=d3524e1962 href="http://www.ncbi.nlm.nih.gov/pubmed/9778212">PubMed Abstract </a> | <a target="xrefwindow" id="d3524e1965" href="https://doi.org/10.1002/1529-0131(199810)41:10<1714::AID-ART3&gt;3.0.CO;2-U">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1007547"><span class="faculty-opinion-icon small"></span></a><a name=d3524e1974 class=n-a></a>Rovin BH, Lu L, Zhang X: A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. <i>Kidney Int.</i> 2002; <b>62</b>(1): 261–5. <a target=xrefwindow id=d3524e1982 href="http://www.ncbi.nlm.nih.gov/pubmed/12081586">PubMed Abstract </a> | <a target=xrefwindow id=d3524e1985 href="https://doi.org/10.1046/j.1523-1755.2002.00438.x">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1007547">Faculty Opinions Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d3524e1999 class=n-a></a>Yang W, Ng P, Zhao M, <i> et al.</i>: Population differences in SLE susceptibility genes: STAT4 and BLK, but not PXK, are associated with systemic lupus erythematosus in Hong Kong Chinese. <i>Genes Immun.</i> 2009; <b>10</b>(3): 219–26. <a target=xrefwindow id=d3524e2010 href="http://www.ncbi.nlm.nih.gov/pubmed/19225526">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2013 href="https://doi.org/10.1038/gene.2009.1">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d3524e2022 class=n-a></a>Jönsen A, Bengtsson AA, Nived O, <i> et al.</i>: Gene-environment interactions in the aetiology of systemic lupus erythematosus. <i>Autoimmunity.</i> 2007; <b>40</b>(8): 613–7. <a target=xrefwindow id=d3524e2033 href="http://www.ncbi.nlm.nih.gov/pubmed/18075795">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2036 href="https://doi.org/10.1080/08916930701511051">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1161691"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2045 class=n-a></a>Seredkina N, Zykova SN, Rekvig OP: Progression of Murine Lupus Nephritis Is Linked to Acquired Renal Dnase1 Deficiency and Not to Up-Regulated Apoptosis. <i>Am J Pathol.</i> 2009; <b>175</b>(1): 97–106. <a target=xrefwindow id=d3524e2053 href="http://www.ncbi.nlm.nih.gov/pubmed/19528352">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2056 href="https://doi.org/10.2353/ajpath.2009.080943">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2059 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2708798">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1161691">Faculty Opinions Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d3524e2072 class=n-a></a>Tiller T, Tsuiji M, Yurasov S, <i> et al.</i>: Autoreactivity in human IgG<sup>+</sup> memory B cells. <i>Immunity.</i> 2007; <b>26</b>(2): 205–13. <a target=xrefwindow id=d3524e2086 href="http://www.ncbi.nlm.nih.gov/pubmed/17306569">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2090 href="https://doi.org/10.1016/j.immuni.2007.01.009">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2093 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1839941">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d3524e2102 class=n-a></a>Herlands RA, Christensen SR, Sweet RA, <i> et al.</i>: T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. <i>Immunity.</i> 2008; <b>29</b>(2): 249–60. <a target=xrefwindow id=d3524e2113 href="http://www.ncbi.nlm.nih.gov/pubmed/18691914">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2116 href="https://doi.org/10.1016/j.immuni.2008.06.009">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2120 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4106705">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d3524e2129 class=n-a></a>Odegard JM, Marks BR, DiPlacido LD, <i> et al.</i>: ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. <i>J Exp Med.</i> 2008; <b>205</b>(12): 2873–86. <a target=xrefwindow id=d3524e2140 href="http://www.ncbi.nlm.nih.gov/pubmed/18981236">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2143 href="https://doi.org/10.1084/jem.20080840">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2147 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2585848">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/725513211"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2157 class=n-a></a>Tipton CM, Fucile CF, Darce J, <i> et al.</i>: Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. <i>Nat Immunol.</i> 2015; <b>16</b>(7): 755–65. <a target=xrefwindow id=d3524e2168 href="http://www.ncbi.nlm.nih.gov/pubmed/26006014">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2171 href="https://doi.org/10.1038/ni.3175">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4512288">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/725513211">Faculty Opinions Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d3524e2188 class=n-a></a>Hoffman W, Lakkis FG, Chalasani G: B Cells, Antibodies, and More. <i>Clin J Am Soc Nephrol.</i> 2016; <b>11</b>(1): 137–54. <a target=xrefwindow id=d3524e2196 href="http://www.ncbi.nlm.nih.gov/pubmed/26700440">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2199 href="https://doi.org/10.2215/CJN.09430915">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2202 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4702236">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d3524e2211 class=n-a></a>Avery DT, Bryant VL, Ma CS, <i> et al.</i>: IL-21-Induced Isotype Switching to IgG and IgA by Human Naive B Cells Is Differentially Regulated by IL-4. <i>J Immunol.</i> 2008; <b>181</b>(3): 1767–79. <a target=xrefwindow id=d3524e2222 href="http://www.ncbi.nlm.nih.gov/pubmed/18641314">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2225 href="https://doi.org/10.4049/jimmunol.181.3.1767">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d3524e2234 class=n-a></a>Vlahakos DV, Foster MH, Adams S, <i> et al.</i>: Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. <i>Kidney Int.</i> 1992; <b>41</b>(6): 1690–700. <a target=xrefwindow id=d3524e2245 href="http://www.ncbi.nlm.nih.gov/pubmed/1501424">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2248 href="https://doi.org/10.1038/ki.1992.242">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d3524e2257 class=n-a></a>Tsao BP, Ohnishi K, Cheroutre H, <i> et al.</i>: Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. <i>J Immunol.</i> 1992; <b>149</b>(1): 350–8. <a target=xrefwindow id=d3524e2268 href="http://www.ncbi.nlm.nih.gov/pubmed/1607661">PubMed Abstract </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d3524e2277 class=n-a></a>Riley JK, Sliwkowski MX: CD20: A gene in search of a function. <i>Semin Oncol.</i> 2000; <b>27</b>(6 Suppl 12): 17–24. <a target=xrefwindow id=d3524e2285 href="http://www.ncbi.nlm.nih.gov/pubmed/11225995">PubMed Abstract </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d3524e2295 class=n-a></a>Tsokos GC: B Cells, Be Gone — B-Cell Depletion in the Treatment of Rheumatoid Arthritis. <i>N Engl J Med.</i> 2004; <b>350</b>(25): 2546–8. <a target=xrefwindow id=d3524e2303 href="http://www.ncbi.nlm.nih.gov/pubmed/15201410">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2306 href="https://doi.org/10.1056/NEJMp048114">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d3524e2315 class=n-a></a>Cordeiro AC, Isenberg DA: Novel therapies in lupus - focus on nephritis. <i>Acta Reumatol Port.</i> 2008; <b>33</b>(2): 157–69. <a target=xrefwindow id=d3524e2323 href="http://www.ncbi.nlm.nih.gov/pubmed/18604181">PubMed Abstract </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718325314"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2332 class=n-a></a>Edwards JCW, Szczepanski L, Szechinski J, <i> et al.</i>: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. <i>N Engl J Med.</i> 2004; <b>350</b>(25): 2572–81. <a target=xrefwindow id=d3524e2343 href="http://www.ncbi.nlm.nih.gov/pubmed/15201414">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2346 href="https://doi.org/10.1056/NEJMoa032534">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718325314">Faculty Opinions Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d3524e2359 class=n-a></a>Bekar KW, Owen T, Dunn R, <i> et al.</i>: Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. <i>Arthritis Rheum.</i> 2010; <b>62</b>(8): 2443–57. <a target=xrefwindow id=d3524e2370 href="http://www.ncbi.nlm.nih.gov/pubmed/20506300">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2373 href="https://doi.org/10.1002/art.27515">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2377 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2920998">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/716597855"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2386 class=n-a></a>Rovin BH, Furie R, Latinis K, <i> et al.</i>: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. <i>Arthritis Rheum.</i> 2012; <b>64</b>(4): 1215–26. <a target=xrefwindow id=d3524e2397 href="http://www.ncbi.nlm.nih.gov/pubmed/22231479">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2400 href="https://doi.org/10.1002/art.34359">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/716597855">Faculty Opinions Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d3524e2413 class=n-a></a>Tobinai K, Klein C, Oya N, <i> et al.</i>: A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. <i>Adv Ther.</i> 2017; <b>34</b>(2): 324–56. <a target=xrefwindow id=d3524e2424 href="http://www.ncbi.nlm.nih.gov/pubmed/28004361">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2427 href="https://doi.org/10.1007/s12325-016-0451-1">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2431 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5331088">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733203375"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2441 class=n-a></a>Freeman CL, Sehn LH: A tale of two antibodies: Obinutuzumab versus rituximab. <i>Br J Haematol.</i> 2018; <b>182</b>(1): 29–45. <a target=xrefwindow id=d3524e2449 href="http://www.ncbi.nlm.nih.gov/pubmed/29741753">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2452 href="https://doi.org/10.1111/bjh.15232">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733203375">Faculty Opinions Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d3524e2465 class=n-a></a>Segerer S, Schlöndorff D: B cells and tertiary lymphoid organs in renal inflammation. <i>Kidney Int.</i> 2008; <b>73</b>(5): 533–7. <a target=xrefwindow id=d3524e2473 href="http://www.ncbi.nlm.nih.gov/pubmed/18094677">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2476 href="https://doi.org/10.1038/sj.ki.5002734">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1031638"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2485 class=n-a></a>Elward K, Griffiths M, Mizuno M, <i> et al.</i>: CD46 Plays a Key Role in Tailoring Innate Immune Recognition of Apoptotic and Necrotic Cells. <i>J Biol Chem.</i> 2005; <b>280</b>(43): 36342–54. <a target=xrefwindow id=d3524e2496 href="http://www.ncbi.nlm.nih.gov/pubmed/16087667">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2499 href="https://doi.org/10.1074/jbc.M506579200">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1031638">Faculty Opinions Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d3524e2512 class=n-a></a>Kawano M, Seya T, Koni I, <i> et al.</i>: Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). <i>Clin Exp Immunol.</i> 1999; <b>116</b>(3): 542–6. <a target=xrefwindow id=d3524e2523 href="http://www.ncbi.nlm.nih.gov/pubmed/10361248">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2526 href="https://doi.org/10.1046/j.1365-2249.1999.00917.x">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2530 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1905304">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/717955958"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2539 class=n-a></a>Weidenbusch M, Römmele C, Schröttle A, <i> et al.</i>: Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. <i>Nephrol Dial Transplant.</i> 2013; <b>28</b>(1): 106–11. <a target=xrefwindow id=d3524e2550 href="http://www.ncbi.nlm.nih.gov/pubmed/22764193">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2553 href="https://doi.org/10.1093/ndt/gfs285">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/717955958">Faculty Opinions Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d3524e2566 class=n-a></a>Díaz-Lagares C, Croca S, Sangle S, <i> et al.</i>: Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. <i>Autoimmun Rev.</i> 2012; <b>11</b>(5): 357–64. <a target=xrefwindow id=d3524e2577 href="http://www.ncbi.nlm.nih.gov/pubmed/22032879">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2580 href="https://doi.org/10.1016/j.autrev.2011.10.009">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d3524e2590 class=n-a></a>Moroni G, Gallelli B, Sinico RA, <i> et al.</i>: Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: A clinical observational study. <i>Ann Rheum Dis.</i> 2012; <b>71</b>(10): 1751–2. <a target=xrefwindow id=d3524e2601 href="http://www.ncbi.nlm.nih.gov/pubmed/22586177">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2604 href="https://doi.org/10.1136/annrheumdis-2012-201442">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718021205"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2613 class=n-a></a>Condon MB, Ashby D, Pepper RJ, <i> et al.</i>: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. <i>Ann Rheum Dis.</i> 2013; <b>72</b>(8): 1280–6. <a target=xrefwindow id=d3524e2624 href="http://www.ncbi.nlm.nih.gov/pubmed/23740227">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2627 href="https://doi.org/10.1136/annrheumdis-2012-202844">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718021205">Faculty Opinions Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d3524e2640 class=n-a></a>Pepper R, Griffith M, Kirwan C, <i> et al.</i>: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. <i>Nephrol Dial Transplant.</i> 2009; <b>24</b>(12): 3717–23. <a target=xrefwindow id=d3524e2651 href="http://www.ncbi.nlm.nih.gov/pubmed/19617257">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2654 href="https://doi.org/10.1093/ndt/gfp336">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d3524e2663 class=n-a></a>Furie R, Aroca G, Alvarez A, <i> et al.</i>: A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>: [Abstract]. <a target=xrefwindow id=d3524e2674 href="https://acrabstracts.org/abstract/a-phase-ii-randomized-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-obinutuzumab-or-placebo-in-combination-with-mycophenolate-mofetil-in-patients-with-active-class-iii/">Reference Source</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d3524e2683 class=n-a></a>Rovin B, Furie R, Aroca G, <i> et al.</i>: B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis. <i>Kidney Int Rep.</i> 2020; <b>5</b>(3): S352 [Abstract]. <a target=xrefwindow id=d3524e2694 href="https://www.kireports.org/article/S2468-0249(20)30966-9/pdf">Reference Source</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/8909956"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2703 class=n-a></a>Navarra SV, Guzmán RM, Gallacher AE, <i> et al.</i>: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2011; <b>377</b>(9767): 721–31. <a target=xrefwindow id=d3524e2714 href="http://www.ncbi.nlm.nih.gov/pubmed/21296403">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2717 href="https://doi.org/10.1016/S0140-6736(10)61354-2">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/8909956">Faculty Opinions Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/717996303"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2731 class=n-a></a>Furie R, Petri M, Zamani O, <i> et al.</i>: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis Rheum.</i> 2011; <b>63</b>(12): 3918–30. <a target=xrefwindow id=d3524e2742 href="http://www.ncbi.nlm.nih.gov/pubmed/22127708">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2745 href="https://doi.org/10.1002/art.30613">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2749 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5007058">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/717996303">Faculty Opinions Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d3524e2762 class=n-a></a>Dooley MA, Houssiau F, Aranow C, <i> et al.</i>: Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE. <i>Lupus.</i> 2012; <b>22</b>(1): 63–72. <a target=xrefwindow id=d3524e2773 href="http://www.ncbi.nlm.nih.gov/pubmed/23263865">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2776 href="https://doi.org/10.1177/0961203312465781">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d3524e2785 class=n-a></a>Stohl W, Hiepe F, Latinis KM, <i> et al.</i>: Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. <i>Arthritis Rheum.</i> 2012; <b>64</b>(7): 2328–37. <a target=xrefwindow id=d3524e2796 href="http://www.ncbi.nlm.nih.gov/pubmed/22275291">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2799 href="https://doi.org/10.1002/art.34400">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2803 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3350827">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d3524e2812 class=n-a></a>GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis. 2019. <a target=xrefwindow id=d3524e2814 href="https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-study-of-benlysta-in-patients-with-lupus-nephritis/">Reference Source</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/725768310"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2823 class=n-a></a>Isenberg DA, Petri M, Kalunian K, <i> et al.</i>: Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: Results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(2): 323–31. <a target=xrefwindow id=d3524e2834 href="http://www.ncbi.nlm.nih.gov/pubmed/26338095">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2837 href="https://doi.org/10.1136/annrheumdis-2015-207653">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/725768310">Faculty Opinions Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/725732407"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2850 class=n-a></a>Merrill JT, van Vollenhoven RF, Buyon JP, <i> et al.</i>: Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: Results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(2): 332–40. <a target=xrefwindow id=d3524e2861 href="http://www.ncbi.nlm.nih.gov/pubmed/26293163">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2864 href="https://doi.org/10.1136/annrheumdis-2015-207654">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/725732407">Faculty Opinions Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d3524e2878 class=n-a></a>Rovin BH, Dooley MA, Radhakrishnan J, <i> et al.</i>: The impact of tabalumab on the kidney in systemic lupus erythematosus: Results from two phase 3 randomized, clinical trials. <i>Lupus.</i> 2016; <b>25</b>(14): 1597–601. <a target=xrefwindow id=d3524e2889 href="http://www.ncbi.nlm.nih.gov/pubmed/27220348">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2892 href="https://doi.org/10.1177/0961203316650734">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/715897974"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2901 class=n-a></a>Ginzler EM, Wax S, Rajeswaran A, <i> et al.</i>: Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. <i>Arthritis Res Ther.</i> 2012; <b>14</b>(1): R33. <a target=xrefwindow id=d3524e2912 href="http://www.ncbi.nlm.nih.gov/pubmed/22325903">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2915 href="https://doi.org/10.1186/ar3738">Publisher Full Text </a> | <a target=xrefwindow id=d3524e2919 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3392829">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/715897974">Faculty Opinions Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d3524e2932 class=n-a></a>Wu D, Li J, Xu D, <i> et al.</i>: A human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-Inducing ligand (APRIL), telitacicept (RC18), in systemic lupus erythematosus (SLE): results of a phase 2b study. <i>Arthritis Rheumatol.</i> 2019; 71 [Abstract]. <a target=xrefwindow id=d3524e2940 href="https://acrabstracts.org/abstract/a-human-recombinant-fusion-protein-targeting-b-lymphocyte-stimulator-blys-and-a-proliferation-inducing-ligand-april-telitacicept-rc18-in-systemic-lupus-erythematosus-sle-results-of-a-phase/">Reference Source</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d3524e2949 class=n-a></a>Dall'Era M, Aranow C, Byron M, <i> et al.</i>: Phase 2 trial of induction therapy with anti-CD20 (RITUXIMAB) followed by maintenance therapy with anti-BAFF (BELIMUMAB) in patients with active lupus nephritis. <i>Ann Rheum Dis.</i> 2018; <b>77</b>: 690 [Abstract]. <a target=xrefwindow id=d3524e2960 href="https://acrabstracts.org/abstract/phase-2-trial-of-induction-therapy-with-anti-cd20-rituximab-followed-by-maintenance-therapy-with-anti-baff-belimumab-in-patients-with-active-lupus-nephritis/">Reference Source</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733027416"><span class="faculty-opinion-icon small"></span></a><a name=d3524e2969 class=n-a></a>Kraaij T, Kamerling SWA, de Rooij ENM, <i> et al.</i>: The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. <i>J Autoimmun.</i> 2018; <b>91</b>: 45–54. <a target=xrefwindow id=d3524e2980 href="http://www.ncbi.nlm.nih.gov/pubmed/29636274">PubMed Abstract </a> | <a target=xrefwindow id=d3524e2983 href="https://doi.org/10.1016/j.jaut.2018.03.003">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733027416">Faculty Opinions Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d3524e2996 class=n-a></a>Teng YKO, Bruce IN, Diamond B, <i> et al.</i>: Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. <i>BMJ Open.</i> 2019; <b>9</b>(3): e025687. <a target=xrefwindow id=d3524e3007 href="http://www.ncbi.nlm.nih.gov/pubmed/30898822">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3010 href="https://doi.org/10.1136/bmjopen-2018-025687">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3014 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6475247">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d3524e3024 class=n-a></a>Merrill J, June J, Koumpouras F, <i> et al.</i>: Phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb5871, in systemic lupus erythematosus (SLE). <i>Ann Rheum Dis.</i> 2019; <b>78</b>: 761–62. <a target=xrefwindow id=d3524e3035 href="https://doi.org/10.1136/annrheumdis-2019-eular.4234">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d3524e3044 class=n-a></a>Alexander T, Sarfert R, Klotsche J, <i> et al.</i>: The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. <i>Ann Rheum Dis.</i> 2015; <b>74</b>(7): 1474–8. <a target=xrefwindow id=d3524e3055 href="http://www.ncbi.nlm.nih.gov/pubmed/25710470">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3058 href="https://doi.org/10.1136/annrheumdis-2014-206016">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3062 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4484251">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d3524e3071 class=n-a></a>Zhang H, Liu Z, Huang L, <i> et al.</i>: The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. <i>Lupus.</i> 2017; <b>26</b>(9): 952–8. <a target=xrefwindow id=d3524e3082 href="http://www.ncbi.nlm.nih.gov/pubmed/28059023">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3085 href="https://doi.org/10.1177/0961203316686703">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d3524e3094 class=n-a></a>Furie R, Bomba D, Dall'era M, <i> et al.</i>: Treatment of systemic lupus erythematosus patients with the immunoproteasome inhibitor KZR-616: results from the first 2 cohorts of an open-label phase 1b dose escalation trial. <i>Ann Rheum Dis.</i> 2019; <b>78</b>: 776–77 [Abstract]. <a target=xrefwindow id=d3524e3105 href="https://doi.org/10.1136/annrheumdis-2019-eular.1955">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d3524e3114 class=n-a></a>Georgopoulos K, Winandy S, Avitahl N: The role of the Ikaros gene in lymphocyte development and homeostasis. <i>Annu Rev Immunol.</i> 1997; <b>15</b>: 155–76. <a target=xrefwindow id=d3524e3122 href="http://www.ncbi.nlm.nih.gov/pubmed/9143685">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3125 href="https://doi.org/10.1146/annurev.immunol.15.1.155">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d3524e3134 class=n-a></a>John LB, Ward AC: The Ikaros gene family: Transcriptional regulators of hematopoiesis and immunity. <i>Mol Immunol.</i> 2011; <b>48</b>(9–10): 1272–8. <a target=xrefwindow id=d3524e3142 href="http://www.ncbi.nlm.nih.gov/pubmed/21477865">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3145 href="https://doi.org/10.1016/j.molimm.2011.03.006">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d3524e3155 class=n-a></a>Hu SJ, Wen Ll, Hu X, <i> et al.</i>: <i>IKZF1</i>: A critical role in the pathogenesis of systemic lupus erythematosus? <i>Mod Rheumatol.</i> 2013; <b>23</b>(2): 205–9. <a target=xrefwindow id=d3524e3169 href="http://www.ncbi.nlm.nih.gov/pubmed/22782532">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3173 href="https://doi.org/10.1007/s10165-012-0706-x">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d3524e3182 class=n-a></a>Wang JH, Avitahl N, Cariappa A, <i> et al.</i>: <i>Aiolos</i> Regulates B Cell Activation and Maturation to Effector State. <i>Immunity.</i> 1998; <b>9</b>(4): 543–53. <a target=xrefwindow id=d3524e3196 href="http://www.ncbi.nlm.nih.gov/pubmed/9806640">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3200 href="https://doi.org/10.1016/s1074-7613(00)80637-8">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d3524e3209 class=n-a></a>Nakayama Y, Kosek J, Capone L, <i> et al.</i>: Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity. <i>J Immunol.</i> 2017; <b>199</b>(7): 2388–407. <a target=xrefwindow id=d3524e3220 href="http://www.ncbi.nlm.nih.gov/pubmed/28848067">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3223 href="https://doi.org/10.4049/jimmunol.1601725">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5602157">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733519000"><span class="faculty-opinion-icon small"></span></a><a name=d3524e3236 class=n-a></a>Schafer PH, Ye Y, Wu L, <i> et al.</i>: Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: Immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(10): 1516–23. <a target=xrefwindow id=d3524e3247 href="http://www.ncbi.nlm.nih.gov/pubmed/29945920">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3250 href="https://doi.org/10.1136/annrheumdis-2017-212916">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3254 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6161670">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733519000">Faculty Opinions Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d3524e3267 class=n-a></a>Furie R, Werth VP, Gaudy A, <i> et al.</i>: A randomized, placebo-controlled, double-blind, ascending-dose, safety, and pharmacokinetics study of CC-220 in subjects with systemic lupus erythematosus. <i>Arthritis Rheumatol.</i> 2017; <b>69</b> [Abstract]. <a target=xrefwindow id=d3524e3278 href="https://acrabstracts.org/abstract/a-randomized-placebo-controlled-double-blind-ascending-dose-safety-and-pharmacokinetics-study-of-cc-220-in-subjects-with-systemic-lupus-erythematosus/">Reference Source</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d3524e3287 class=n-a></a>Werth VP, Furie R, Gaudy A, <i> et al.</i>: CC-220 decreases B-cell subsets and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients and is associated with skin improvement: pharmacodynamic results from a phase IIa proof of concept study. <i>Arthritis Rheumatol.</i> 2017; <b>69</b> [Abstract]. <a target=xrefwindow id=d3524e3298 href="https://acrabstracts.org/abstract/cc-220-decreases-b-cell-subsets-and-plasmacytoid-dendritic-cells-in-systemic-lupus-erythematosus-sle-patients-and-is-associated-with-skin-improvement-pharmacodynamic-results-from-a-phase-iia-proof/">Reference Source</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d3524e3308 class=n-a></a>Mak A, Kow NY: The pathology of T cells in systemic lupus erythematosus. <i>J Immunol Res.</i> 2014; <b>2014</b>: 419029. <a target=xrefwindow id=d3524e3316 href="http://www.ncbi.nlm.nih.gov/pubmed/24864268">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3319 href="https://doi.org/10.1155/2014/419029">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3322 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4017881">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d3524e3331 class=n-a></a>Dutta D, Barr VA, Akpan I, <i> et al.</i>: Recruitment of calcineurin to the TCR positively regulates T cell activation. <i>Nat Immunol.</i> 2017; <b>18</b>(2): 196–204. <a target=xrefwindow id=d3524e3342 href="http://www.ncbi.nlm.nih.gov/pubmed/27941787">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3345 href="https://doi.org/10.1038/ni.3640">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3349 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6352896">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d3524e3358 class=n-a></a>Ekberg H, van Gelder T, Kaplan B, <i> et al.</i>: Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. <i>Transplantation.</i> 2011; <b>92</b>(1): 82–7. <a target=xrefwindow id=d3524e3369 href="http://www.ncbi.nlm.nih.gov/pubmed/21562449">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3372 href="https://doi.org/10.1097/TP.0b013e31821fad06">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732076452"><span class="faculty-opinion-icon small"></span></a><a name=d3524e3381 class=n-a></a>Fu J, Wang Z, Lee K, <i> et al.</i>: Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. <i>Kidney Int.</i> 2018; <b>93</b>(2): 416–29. <a target=xrefwindow id=d3524e3392 href="http://www.ncbi.nlm.nih.gov/pubmed/29102373">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3395 href="https://doi.org/10.1016/j.kint.2017.08.031">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732076452">Faculty Opinions Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1119497"><span class="faculty-opinion-icon small"></span></a><a name=d3524e3408 class=n-a></a>Faul C, Donnelly M, Merscher-Gomez S, <i> et al.</i>: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. <i>Nat Med.</i> 2008; <b>14</b>(9): 931–8. <a target=xrefwindow id=d3524e3419 href="http://www.ncbi.nlm.nih.gov/pubmed/18724379">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3422 href="https://doi.org/10.1038/nm.1857">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3426 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4109287">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1119497">Faculty Opinions Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d3524e3439 class=n-a></a>Coward RJM, Foster RR, Patton D, <i> et al.</i>: Nephrotic Plasma Alters Slit Diaphragm–Dependent Signaling and Translocates Nephrin, Podocin, and CD2 Associated Protein in Cultured Human Podocytes. <i>J Am Soc Nephrol.</i> 2005; <b>16</b>(3): 629–37. <a target=xrefwindow id=d3524e3450 href="http://www.ncbi.nlm.nih.gov/pubmed/15659563">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3453 href="https://doi.org/10.1681/ASN.2004030172">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d3524e3463 class=n-a></a>Chen W, Tang X, Liu Q, <i> et al.</i>: Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. <i>Am J Kidney Dis.</i> 2011; <b>57</b>(2): 235–44. <a target=xrefwindow id=d3524e3474 href="http://www.ncbi.nlm.nih.gov/pubmed/21177013">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3477 href="https://doi.org/10.1053/j.ajkd.2010.08.036">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d3524e3486 class=n-a></a>Liu Z, Zhang H, Liu Z, <i> et al.</i>: Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial. <i>Ann Intern Med.</i> 2015; <b>162</b>(1): 18–26. <a target=xrefwindow id=d3524e3497 href="http://www.ncbi.nlm.nih.gov/pubmed/25383558">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3500 href="https://doi.org/10.7326/M14-1030">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d3524e3509 class=n-a></a>Mok CC, Ying KY, Yim CW, <i> et al.</i>: Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(1): 30–6. <a target=xrefwindow id=d3524e3520 href="http://www.ncbi.nlm.nih.gov/pubmed/25550339">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3523 href="https://doi.org/10.1136/annrheumdis-2014-206456">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d3524e3532 class=n-a></a>Zhang H, Liu Z, Zhou M, <i> et al.</i>: Multitarget Therapy for Maintenance Treatment of Lupus Nephritis. <i> J Am Soc Nephrol.</i> 2017; <b>28</b>(12): 3671–8. <a target=xrefwindow id=d3524e3543 href="http://www.ncbi.nlm.nih.gov/pubmed/28760751">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3546 href="https://doi.org/10.1681/ASN.2017030263">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3550 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5698076">Free Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732759617"><span class="faculty-opinion-icon small"></span></a><a name=d3524e3559 class=n-a></a>Choi CB, Won S, Bae SC: Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. <i>Lupus.</i> 2018; <b>27</b>(6): 1007–11. <a target=xrefwindow id=d3524e3567 href="http://www.ncbi.nlm.nih.gov/pubmed/29448881">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3570 href="https://doi.org/10.1177/0961203318758505">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732759617">Faculty Opinions Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733658196"><span class="faculty-opinion-icon small"></span></a><a name=d3524e3583 class=n-a></a>Park DJ, Kang JH, Lee KE, <i> et al.</i>: Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: A nationwide multicentre study. <i>Clin Exp Rheumatol.</i> 2019; <b>37</b>(1): 89–96. <a target=xrefwindow id=d3524e3594 href="http://www.ncbi.nlm.nih.gov/pubmed/29998829">PubMed Abstract </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733658196">Faculty Opinions Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d3524e3608 class=n-a></a>Tanaka H, Watanabe S, Aizawa-Yashiro T, <i> et al.</i>: Long-Term Tacrolimus-Based Immunosuppressive Treatment for Young Patients with Lupus Nephritis: A Prospective Study in Daily Clinical Practice. <i> Nephron Clin Pract.</i> 2013; <b>121</b>(3–4): c165–c173. <a target=xrefwindow id=d3524e3619 href="http://www.ncbi.nlm.nih.gov/pubmed/23327881">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3622 href="https://doi.org/10.1159/000346149">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d3524e3631 class=n-a></a>Kise T, Yoshimura H, Fukuyama S, <i> et al.</i>: Successful treatment with mycophenolate mofetil and tacrolimus in juvenile severe lupus nephritis. <i> Case Rep Pediatr.</i> 2015; <b>2015</b>: 651803. <a target=xrefwindow id=d3524e3642 href="http://www.ncbi.nlm.nih.gov/pubmed/25785217">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3645 href="https://doi.org/10.1155/2015/651803">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3649 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4346693">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d3524e3658 class=n-a></a>Dall'Era M, Cisternas MG, Smilek DE, <i> et al.</i>: Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort. <i> Arthritis Rheumatol.</i> 2015; <b>67</b>(5): 1305–13. <a target=xrefwindow id=d3524e3669 href="http://www.ncbi.nlm.nih.gov/pubmed/25605554">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3672 href="https://doi.org/10.1002/art.39026">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d3524e3681 class=n-a></a>Chan TM: Preventing renal failure in patients with severe lupus nephritis. <i>Kidney Int Suppl.</i> 2005; (94): S116–9. <a target=xrefwindow id=d3524e3686 href="http://www.ncbi.nlm.nih.gov/pubmed/15752227">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3689 href="https://doi.org/10.1111/j.1523-1755.2005.09427.x">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d3524e3698 class=n-a></a>Yap DYH, Ma MKM, Mok MMY, <i> et al.</i>: Long-term data on tacrolimus treatment in lupus nephritis. <i>Rheumatology (Oxford).</i> 2014; <b>53</b>(12): 2232–7. <a target=xrefwindow id=d3524e3709 href="http://www.ncbi.nlm.nih.gov/pubmed/24996908">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3712 href="https://doi.org/10.1093/rheumatology/keu265">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d3524e3721 class=n-a></a>Praga M, Barrio V, Juárez GF, <i> et al.</i>: Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. <i>Kidney Int.</i> 2007; <b>71</b>(9): 924–30. <a target=xrefwindow id=d3524e3732 href="http://www.ncbi.nlm.nih.gov/pubmed/17377504">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3735 href="https://doi.org/10.1038/sj.ki.5002215">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1158639"><span class="faculty-opinion-icon small"></span></a><a name=d3524e3745 class=n-a></a>Austin HA, Illei GG, Braun MJ, <i> et al.</i>: Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy. <i>J Am Soc Nephrol.</i> 2009; <b>20</b>(4): 901–11. <a target=xrefwindow id=d3524e3756 href="http://www.ncbi.nlm.nih.gov/pubmed/19297556">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3759 href="https://doi.org/10.1681/ASN.2008060665">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3763 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2663831">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1158639">Faculty Opinions Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d3524e3776 class=n-a></a>Mok CC: Calcineurin inhibitors in systemic lupus erythematosus. <i>Best Pract Res Clin Rheumatol.</i> 2017; <b>31</b>(3): 429–38. <a target=xrefwindow id=d3524e3784 href="http://www.ncbi.nlm.nih.gov/pubmed/29224682">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3787 href="https://doi.org/10.1016/j.berh.2017.09.010">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734005165"><span class="faculty-opinion-icon small"></span></a><a name=d3524e3796 class=n-a></a>Sin FE, Isenberg D: An evaluation of voclosporin for the treatment of lupus nephritis. <i>Expert Opin Pharmacother.</i> 2018; <b>19</b>(14): 1613–21. <a target=xrefwindow id=d3524e3804 href="http://www.ncbi.nlm.nih.gov/pubmed/30207816">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3807 href="https://doi.org/10.1080/14656566.2018.1516751">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734005165">Faculty Opinions Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735916359"><span class="faculty-opinion-icon small"></span></a><a name=d3524e3820 class=n-a></a>Dörner T, Furie R: Novel paradigms in systemic lupus erythematosus. <i>Lancet.</i> 2019; <b>393</b>(10188): 2344–58. <a target=xrefwindow id=d3524e3828 href="http://www.ncbi.nlm.nih.gov/pubmed/31180031">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3831 href="https://doi.org/10.1016/S0140-6736(19)30546-X">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735916359">Faculty Opinions Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734432447"><span class="faculty-opinion-icon small"></span></a><a name=d3524e3844 class=n-a></a>Rovin BH, Solomons N, Pendergraft WF, <i> et al.</i>: A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. <i>Kidney Int.</i> 2019; <b>95</b>(1): 219–31. <a target=xrefwindow id=d3524e3855 href="http://www.ncbi.nlm.nih.gov/pubmed/30420324">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3858 href="https://doi.org/10.1016/j.kint.2018.08.025">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734432447">Faculty Opinions Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d3524e3871 class=n-a></a>Gibson KL, Parikh S, Saxena A, <i> et al.</i>: AURORA phase 3 trial demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). <i>Am J Kidney Dis.</i> 2020; <b>75</b>(5): 819 [Abstract]. <a target=xrefwindow id=d3524e3882 href="https://www.clinicalkey.com/#!/content/1-s2.0-S0272638620305771">Reference Source</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d3524e3892 class=n-a></a>Mihara M, Tan I, Chuzhin Y, <i> et al.</i>: CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. <i>J Clin Invest.</i> 2000; <b>106</b>(1): 91–101. <a target=xrefwindow id=d3524e3903 href="http://www.ncbi.nlm.nih.gov/pubmed/10880052">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3906 href="https://doi.org/10.1172/JCI9244">Publisher Full Text </a> | <a target=xrefwindow id=d3524e3910 href="http://www.ncbi.nlm.nih.gov/pmc/articles/314360">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d3524e3919 class=n-a></a>Waterhouse P, Penninger JM, Timms E, <i> et al.</i>: Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>. <i>Science.</i> 1995; <b>270</b>(5238): 985–8. <a target=xrefwindow id=d3524e3933 href="http://www.ncbi.nlm.nih.gov/pubmed/7481803">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3937 href="https://doi.org/10.1126/science.270.5238.985">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d3524e3946 class=n-a></a>Dall'Era M, Davis J: CTLA4Ig: A novel inhibitor of costimulation. <i>Lupus.</i> 2004; <b>13</b>(5): 372–6. <a target=xrefwindow id=d3524e3954 href="http://www.ncbi.nlm.nih.gov/pubmed/15230295">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3957 href="https://doi.org/10.1191/0961203303lu1029oa">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d3524e3966 class=n-a></a>Daikh DI, Wofsy D: Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide. <i> J Immunol.</i> 2001; <b>166</b>(5): 2913–6. <a target=xrefwindow id=d3524e3974 href="http://www.ncbi.nlm.nih.gov/pubmed/11207238">PubMed Abstract </a> | <a target=xrefwindow id=d3524e3977 href="https://doi.org/10.4049/jimmunol.166.5.2913">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d3524e3986 class=n-a></a>Furie R, Nicholls K, Cheng TT, <i> et al.</i>: Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. <i> Arthritis Rheumatol.</i> 2014; <b>66</b>(2): 379–89. <a target=xrefwindow id=d3524e3997 href="http://www.ncbi.nlm.nih.gov/pubmed/24504810">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4000 href="https://doi.org/10.1002/art.38260">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d3524e4009 class=n-a></a>Furie R, Dooley MA, Wofsy D, <i> et al.</i>: A phase III randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class III or IV lupus nephritis. <i>Ann Rheum Dis.</i> 2020; <b>77</b>: 176 [Abstract]. <a target=xrefwindow id=d3524e4020 href="https://acrabstracts.org/abstract/a-phase-iii-randomized-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-abatacept-or-placebo-on-standard-of-care-in-patients-with-active-class-iii-or-iv-lupus-nephritis/">Reference Source</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/717971077"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4030 class=n-a></a>Wofsy D, Hillson JL, Diamond B: Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. <i>Arthritis Rheum.</i> 2012; <b>64</b>(11): 3660–5. <a target=xrefwindow id=d3524e4038 href="http://www.ncbi.nlm.nih.gov/pubmed/22806274">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4041 href="https://doi.org/10.1002/art.34624">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/717971077">Faculty Opinions Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718171020"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4054 class=n-a></a>Yu CC, Fornoni A, Weins A, <i> et al.</i>: Abatacept in B7-1-positive proteinuric kidney disease. <i>N Engl J Med.</i> 2013; <b>369</b>(25): 2416–23. <a target=xrefwindow id=d3524e4065 href="http://www.ncbi.nlm.nih.gov/pubmed/24206430">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4068 href="https://doi.org/10.1056/NEJMoa1304572">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4072 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3951406">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718171020">Faculty Opinions Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726197482"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4085 class=n-a></a>Reiser J, von Gersdorff G, Loos M, <i> et al.</i>: Induction of B7-1 in podocytes is associated with nephrotic syndrome. <i>J Clin Invest.</i> 2004; <b>113</b>(10): 1390–7. <a target=xrefwindow id=d3524e4096 href="http://www.ncbi.nlm.nih.gov/pubmed/15146236">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4099 href="https://doi.org/10.1172/JCI20402">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4103 href="http://www.ncbi.nlm.nih.gov/pmc/articles/406528">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726197482">Faculty Opinions Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d3524e4116 class=n-a></a>Furie R, Bruce I, Dorner T, <i> et al.</i>: Efficacy and safety of dapirolizumab pegol (DZP) in patients with moderately to severely active systemic lupus erythematosus (SLE): A randomized, placebo (PBO)-controlled study. <i>Ann Rheum Dis.</i> 2019; <b>78</b>: 775–76. <a target=xrefwindow id=d3524e4127 href="https://acrabstracts.org/abstract/efficacy-and-safety-of-dapirolizumab-pegol-in-patients-with-moderately-to-severely-active-systemic-lupus-erythematosus-a-randomized-placebo-controlled-study/">Reference Source</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726197482"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4136 class=n-a></a>Koga T, Ichinose K, Kawakami A, <i> et al.</i>: The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target. <i>Expert Rev Clin Immunol.</i> 2019; <b>15</b>(6): 629–37. <a target=xrefwindow id=d3524e4147 href="http://www.ncbi.nlm.nih.gov/pubmed/30874446">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4150 href="https://doi.org/10.1080/1744666X.2019.1593141">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726197482">Faculty Opinions Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d3524e4163 class=n-a></a>Zhang C, Chan CCY, Cheung KF, <i> et al.</i>: Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis. <i>Clin Sci (Lond).</i> 2019; <b>133</b>(15): 1721–44. <a target=xrefwindow id=d3524e4174 href="http://www.ncbi.nlm.nih.gov/pubmed/31358596">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4177 href="https://doi.org/10.1042/CS20190536">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d3524e4187 class=n-a></a>Lui SL, Yung S, Tsang R, <i> et al.</i>: Rapamycin prevents the development of nephritis in lupus-prone NZB/W F<sub>1</sub> mice. <i>Lupus.</i> 2008; <b>17</b>(4): 305–13. <a target=xrefwindow id=d3524e4201 href="http://www.ncbi.nlm.nih.gov/pubmed/18413412">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4205 href="https://doi.org/10.1177/0961203307088289">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d3524e4214 class=n-a></a>Stylianou K, Petrakis I, Mavroeidi V, <i> et al.</i>: The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. <i>Nephrol Dial Transplant.</i> 2011; <b>26</b>(2): 498–508. <a target=xrefwindow id=d3524e4225 href="http://www.ncbi.nlm.nih.gov/pubmed/20709738">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4228 href="https://doi.org/10.1093/ndt/gfq496">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d3524e4237 class=n-a></a>Alperovich G, Rama I, Lloberas N, <i> et al.</i>: New immunosuppresor strategies in the treatment of murine lupus nephritis. <i>Lupus.</i> 2007; <b>16</b>(1): 18–24. <a target=xrefwindow id=d3524e4248 href="http://www.ncbi.nlm.nih.gov/pubmed/17283580">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4251 href="https://doi.org/10.1177/0961203306073136">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d3524e4260 class=n-a></a>Lui SL, Tsang R, Chan KW, <i> et al.</i>: Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F<sub>1</sub> mice. <i>Nephrol Dial Transplant.</i> 2008; <b>23</b>(9): 2768–76. <a target=xrefwindow id=d3524e4274 href="http://www.ncbi.nlm.nih.gov/pubmed/18445640">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4278 href="https://doi.org/10.1093/ndt/gfn216">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732868595"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4287 class=n-a></a>Lai ZW, Kelly R, Winans T, <i> et al.</i>: Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: A single-arm, open-label, phase 1/2 trial. <i>Lancet.</i> 2018; <b>391</b>(10126): 1186–96. <a target=xrefwindow id=d3524e4298 href="http://www.ncbi.nlm.nih.gov/pubmed/29551338">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4301 href="https://doi.org/10.1016/S0140-6736(18)30485-9">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4305 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5891154">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732868595">Faculty Opinions Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d3524e4318 class=n-a></a>Yap DYH, Ma MKM, Tang CS, <i> et al.</i>: Proliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience. <i>Nephrology (Carlton).</i> 2012; <b>17</b>(8): 676–80. <a target=xrefwindow id=d3524e4329 href="http://www.ncbi.nlm.nih.gov/pubmed/22817609">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4332 href="https://doi.org/10.1111/j.1440-1797.2012.01646.x">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d3524e4342 class=n-a></a>Yap DYH, Tang C, Chan GCW, <i> et al.</i>: Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis. <i>J Rheumatol.</i> 2018; <b>45</b>(12): 1663–70. <a target=xrefwindow id=d3524e4353 href="http://www.ncbi.nlm.nih.gov/pubmed/30275264">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4356 href="https://doi.org/10.3899/jrheum.180507">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733677639"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4365 class=n-a></a>Wallace DJ, Furie RA, Tanaka Y, <i> et al.</i>: Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet.</i> 2018; <b>392</b>(10143): 222–31. <a target=xrefwindow id=d3524e4376 href="http://www.ncbi.nlm.nih.gov/pubmed/30043749">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4379 href="https://doi.org/10.1016/S0140-6736(18)31363-1">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733677639">Faculty Opinions Recommendation</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d3524e4392 class=n-a></a>Kahl L, Patel J, Layton M, <i> et al.</i>: Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. <i>Lupus.</i> 2016; <b>25</b>(13): 1420–30. <a target=xrefwindow id=d3524e4403 href="http://www.ncbi.nlm.nih.gov/pubmed/27055521">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4406 href="https://doi.org/10.1177/0961203316640910">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d3524e4415 class=n-a></a>van Vollenhoven RF, Layton M, Kahl L, <i> et al.</i>: DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. <i>Lupus.</i> 2015; <b>24</b>(6): 648–9. <a target=xrefwindow id=d3524e4426 href="http://www.ncbi.nlm.nih.gov/pubmed/25724932">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4429 href="https://doi.org/10.1177/0961203315573347">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d3524e4438 class=n-a></a>Singhal S, Shah V, Crater C, <i> et al.</i>: Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY). <i>Lupus Sci Med.</i> 2019; <b>6</b>(Suppl 1): A5–A6 [Abstract]. <a target=xrefwindow id=d3524e4449 href="https://doi.org/10.1136/lupus-2019-lsm.5">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734257854"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4458 class=n-a></a>Chalmers SA, Glynn E, Garcia SJ, <i> et al.</i>: BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. <i>Clin Immunol.</i> 2018; <b>197</b>: 205–18. <a target=xrefwindow id=d3524e4469 href="http://www.ncbi.nlm.nih.gov/pubmed/30339790">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4472 href="https://doi.org/10.1016/j.clim.2018.10.008">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4476 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6384222">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734257854">Faculty Opinions Recommendation</a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d3524e4490 class=n-a></a>Isenberg D, Furie R, Jones N, <i> et al.</i>: Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor, fenebrutinib (GDC-0853), in moderate to severe systemic lupus erythematosus: results of a phase 2 randomized controlled trial. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>(suppl 10): [Abstract]. <a target=xrefwindow id=d3524e4501 href="https://acrabstracts.org/abstract/efficacy-safety-and-pharmacodynamic-effects-of-the-brutons-tyrosine-kinase-inhibitor-fenebrutinib-gdc-0853-in-moderate-to-severe-systemic-lupus-erythematosus-results-of-a-phase-2-rando/">Reference Source</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726989983"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4510 class=n-a></a>Furie R, Khamashta M, Merrill JT, <i> et al.</i>: Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. <i>Arthritis Rheumatol.</i> 2017; <b>69</b>(2): 376–86. <a target=xrefwindow id=d3524e4521 href="http://www.ncbi.nlm.nih.gov/pubmed/28130918">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4524 href="https://doi.org/10.1002/art.39962">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4528 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5299497">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726989983">Faculty Opinions Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737043169"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4541 class=n-a></a>Furie RA, Morand EF, Bruce IN, <i> et al.</i>: Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. <i>Lancet Rheumatol.</i> 2019; <b>1</b>(4): e208–e219. <a target=xrefwindow id=d3524e4552 href="https://doi.org/10.1016/S2665-9913(19)30076-1">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737043169">Faculty Opinions Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737102728"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4565 class=n-a></a>Morand EF, Furie R, Tanaka Y, <i> et al.</i>: Trial of Anifrolumab in Active Systemic Lupus Erythematosus. <i>N Engl J Med.</i> 2020; <b>382</b>(3): 211–21. <a target=xrefwindow id=d3524e4576 href="http://www.ncbi.nlm.nih.gov/pubmed/31851795">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4579 href="https://doi.org/10.1056/NEJMoa1912196">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737102728">Faculty Opinions Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d3524e4592 class=n-a></a>Humrich JY, Morbach H, Undeutsch R, <i> et al.</i>: Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. <i>Proc Natl Acad Sci U S A.</i> 2010; <b>107</b>(1): 204–9. <a target=xrefwindow id=d3524e4603 href="http://www.ncbi.nlm.nih.gov/pubmed/20018660">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4606 href="https://doi.org/10.1073/pnas.0903158107">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4610 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2806746">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d3524e4619 class=n-a></a>Humrich JY, Riemekasten G: Low-dose IL-2 therapy - a complex scenario that remains to be further explored. <i>Nat Rev Rheumatol.</i> 2017; <b>13</b>(6): 386. <a target=xrefwindow id=d3524e4627 href="http://www.ncbi.nlm.nih.gov/pubmed/28490788">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4630 href="https://doi.org/10.1038/nrrheum.2017.71">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726619783"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4640 class=n-a></a>He J, Zhang X, Wei Y, <i> et al.</i>: Low-dose interleukin-2 treatment selectively modulates CD4<sup>+</sup> T cell subsets in patients with systemic lupus erythematosus. <i>Nat Med.</i> 2016; <b>22</b>(9): 991–3. <a target=xrefwindow id=d3524e4654 href="http://www.ncbi.nlm.nih.gov/pubmed/27500725">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4658 href="https://doi.org/10.1038/nm.4148">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726619783">Faculty Opinions Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d3524e4671 class=n-a></a>von Spee-Mayer C, Siegert E, Abdirama D, <i> et al.</i>: Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(7): 1407–15. <a target=xrefwindow id=d3524e4682 href="http://www.ncbi.nlm.nih.gov/pubmed/26324847">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4685 href="https://doi.org/10.1136/annrheumdis-2015-207776">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736643913"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4694 class=n-a></a>He J, Zhang R, Shao M, <i> et al.</i>: Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial. <i>Ann Rheum Dis.</i> 2019; <b>79</b>(1): 141–9. <a target=xrefwindow id=d3524e4705 href="http://www.ncbi.nlm.nih.gov/pubmed/31537547">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4708 href="https://doi.org/10.1136/annrheumdis-2019-215396">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4712 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6937406">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736643913">Faculty Opinions Recommendation</a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d3524e4725 class=n-a></a>Thurman JM, Nester CM: All Things Complement. <i>Clin J Am Soc Nephrol.</i> 2016; <b>11</b>(10): 1856–66. <a target=xrefwindow id=d3524e4733 href="http://www.ncbi.nlm.nih.gov/pubmed/27340286">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4736 href="https://doi.org/10.2215/CJN.01710216">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4739 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5053787">Free Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d3524e4748 class=n-a></a>Trouw LA, Pickering MC, Blom AM: The complement system as a potential therapeutic target in rheumatic disease. <i>Nat Rev Rheumatol.</i> 2017; <b>13</b>(9): 538–47. <a target=xrefwindow id=d3524e4756 href="http://www.ncbi.nlm.nih.gov/pubmed/28794515">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4759 href="https://doi.org/10.1038/nrrheum.2017.125">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d3524e4768 class=n-a></a>Simon-Tillaux N, Chauvet S, El mehdi D, <i> et al.</i>: APL-2 prevents both C3 and C5 convertase formation and activity: a potential therapeutic for renal diseases. <i>J Am Soc Nephrol.</i> 2019; <b>30</b>: 918 [Abstract]. </span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d3524e4787 class=n-a></a>Dixon BP, Greenbaum LA, Huang L, <i> et al.</i>: C3 inhibition with APL-2 targets the underlying disease process of C3G complement hyperactivity and improves proteinuria. <i>J Am Soc Nephrol.</i> 2019; <b>30</b>: 676 [Abstract]. </span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d3524e4805 class=n-a></a>Apellis stopping development of APL-2 for lupus nephritis after completion of phase 2 trial. 2019. <a target=xrefwindow id=d3524e4807 href="https://lupusnewstoday.com/2019/10/21/apellis-to-stop-developing-apl-2-for-lupus-nephritis-after-phase-2-trial/">Reference Source</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d3524e4816 class=n-a></a>Wang Y, Hu Q, Madri JA, <i> et al.</i>: Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. <i>Proc Natl Acad Sci U S A.</i> 1996; <b>93</b>(16): 8563–8. <a target=xrefwindow id=d3524e4827 href="http://www.ncbi.nlm.nih.gov/pubmed/8710910">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4830 href="https://doi.org/10.1073/pnas.93.16.8563">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4834 href="http://www.ncbi.nlm.nih.gov/pmc/articles/38712">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d3524e4843 class=n-a></a>Sciascia S, Radin M, Yazdany J, <i> et al.</i>: Expanding the therapeutic options for renal involvement in lupus: Eculizumab, available evidence. <i>Rheumatol Int.</i> 2017; <b>37</b>(8): 1249–55. <a target=xrefwindow id=d3524e4854 href="http://www.ncbi.nlm.nih.gov/pubmed/28258475">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4857 href="https://doi.org/10.1007/s00296-017-3686-5">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d3524e4866 class=n-a></a>Furie R, Matis L, Rollins SA, <i> et al.</i>: A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus. <i>Arthritis Rheum.</i> 2004; <b>50</b>: [Abstract]. </span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d3524e4884 class=n-a></a>Bao L, Cunningham PN, Quigg RJ: Complement in Lupus Nephritis: New Perspectives. <i>Kidney Dis (Basel).</i> 2015; <b>1</b>(2): 91–9. <a target=xrefwindow id=d3524e4892 href="http://www.ncbi.nlm.nih.gov/pubmed/27536669">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4895 href="https://doi.org/10.1159/000431278">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4898 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4934819">Free Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/725237531"><span class="faculty-opinion-icon small"></span></a><a name=d3524e4908 class=n-a></a>Zuber J, Fakhouri F, Roumenina LT, <i> et al.</i>: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. <i>Nat Rev Nephrol.</i> 2012; <b>8</b>(11): 643–57. <a target=xrefwindow id=d3524e4919 href="http://www.ncbi.nlm.nih.gov/pubmed/23026949">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4922 href="https://doi.org/10.1038/nrneph.2012.214">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/725237531">Faculty Opinions Recommendation</a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d3524e4935 class=n-a></a>Strakhan M, Hurtado-Sbordoni M, Galeas N, <i> et al.</i>: 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: A case report and review of literature. <i>Case Rep Hematol.</i> 2014; <b>2014</b>: 704371. <a target=xrefwindow id=d3524e4946 href="http://www.ncbi.nlm.nih.gov/pubmed/25389502">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4949 href="https://doi.org/10.1155/2014/704371">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4953 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4214168">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d3524e4962 class=n-a></a>Pickering MC, Ismajli M, Condon MB, <i> et al.</i>: Eculizumab as Rescue Therapy in Severe Resistant Lupus Nephritis. <i>Rheumatology (Oxford).</i> 2015; <b>54</b>(12): 2286–8. <a target=xrefwindow id=d3524e4973 href="http://www.ncbi.nlm.nih.gov/pubmed/26316577">PubMed Abstract </a> | <a target=xrefwindow id=d3524e4976 href="https://doi.org/10.1093/rheumatology/kev307">Publisher Full Text </a> | <a target=xrefwindow id=d3524e4980 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4643725">Free Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d3524e4989 class=n-a></a>Song D, Guo WY, Wang FM, <i> et al.</i>: Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis. <i>Am J Med Sci.</i> 2017; <b>353</b>(3): 247–57. <a target=xrefwindow id=d3524e5000 href="http://www.ncbi.nlm.nih.gov/pubmed/28262211">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5003 href="https://doi.org/10.1016/j.amjms.2017.01.005">Publisher Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d3524e5012 class=n-a></a>Watanabe H, Garnier G, Circolo A, <i> et al.</i>: Modulation of Renal Disease in MRL/<i>lpr</i> Mice Genetically Deficient in the Alternative Complement Pathway Factor B. <i>J Immunol.</i> 2000; <b>164</b>(2): 786–94. <a target=xrefwindow id=d3524e5026 href="http://www.ncbi.nlm.nih.gov/pubmed/10623824">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5030 href="https://doi.org/10.4049/jimmunol.164.2.786">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735422935"><span class="faculty-opinion-icon small"></span></a><a name=d3524e5039 class=n-a></a>Schubart A, Anderson K, Mainolfi N, <i> et al.</i>: Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. <i>Proc Natl Acad Sci U S A.</i> 2019; <b>116</b>(16): 7926–31. <a target=xrefwindow id=d3524e5050 href="http://www.ncbi.nlm.nih.gov/pubmed/30926668">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5053 href="https://doi.org/10.1073/pnas.1820892116">Publisher Full Text </a> | <a target=xrefwindow id=d3524e5057 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6475383">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735422935">Faculty Opinions Recommendation</a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737402831"><span class="faculty-opinion-icon small"></span></a><a name=d3524e5071 class=n-a></a>Mainolfi N, Ehara T, Karki RG, <i> et al.</i>: Discovery of 4-((2 <i>S</i>,4 <i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1 <i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. <i>J Med Chem.</i> 2020; <b>63</b>(11): 5697–722. <a target=xrefwindow id=d3524e5092 href="http://www.ncbi.nlm.nih.gov/pubmed/32073845">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5095 href="https://doi.org/10.1021/acs.jmedchem.9b01870">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737402831">Faculty Opinions Recommendation</a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d3524e5108 class=n-a></a>Omeros reports more positive data in OMS721 phase 2 trial in renal diseases. 2017. <a target=xrefwindow id=d3524e5110 href="https://investor.omeros.com/news-releases/news-release-details/omeros-reports-more-positive-data-oms721-phase-2-trial-renal">Reference Source</a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d3524e5119 class=n-a></a>Complement-mediated disease: Lupus nephritis. 2020. <a target=xrefwindow id=d3524e5121 href="https://www.omeros.com/research-areas/">Reference Source</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d3524e5130 class=n-a></a>Mantovani A, Cassatella MA, Costantini C, <i> et al.</i>: Neutrophils in the activation and regulation of innate and adaptive immunity. <i>Nat Rev Immunol.</i> 2011; <b>11</b>(5): 519–31. <a target=xrefwindow id=d3524e5141 href="http://www.ncbi.nlm.nih.gov/pubmed/21785456">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5144 href="https://doi.org/10.1038/nri3024">Publisher Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d3524e5153 class=n-a></a>Brinkmann V, Zychlinsky A: Neutrophil extracellular traps: Is immunity the second function of chromatin? <i>J Cell Biol.</i> 2012; <b>198</b>(5): 773–83. <a target=xrefwindow id=d3524e5161 href="http://www.ncbi.nlm.nih.gov/pubmed/22945932">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5164 href="https://doi.org/10.1083/jcb.201203170">Publisher Full Text </a> | <a target=xrefwindow id=d3524e5167 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3432757">Free Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/9075956"><span class="faculty-opinion-icon small"></span></a><a name=d3524e5176 class=n-a></a>Garcia-Romo GS, Caielli S, Vega B, <i> et al.</i>: Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. <i>Sci Transl Med.</i> 2011; <b>3</b>(73): 73ra20. <a target=xrefwindow id=d3524e5187 href="http://www.ncbi.nlm.nih.gov/pubmed/21389264">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5190 href="https://doi.org/10.1126/scitranslmed.3001201">Publisher Full Text </a> | <a target=xrefwindow id=d3524e5194 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3143837">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/9075956">Faculty Opinions Recommendation</a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726082233"><span class="faculty-opinion-icon small"></span></a><a name=d3524e5208 class=n-a></a>Lood C, Blanco LP, Purmalek MM, <i> et al.</i>: Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. <i>Nat Med.</i> 2016; <b>22</b>(2): 146–53. <a target=xrefwindow id=d3524e5219 href="http://www.ncbi.nlm.nih.gov/pubmed/26779811">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5222 href="https://doi.org/10.1038/nm.4027">Publisher Full Text </a> | <a target=xrefwindow id=d3524e5226 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4742415">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726082233">Faculty Opinions Recommendation</a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d3524e5239 class=n-a></a>Jeannin P, Jaillon S, Delneste Y: Pattern recognition receptors in the immune response against dying cells. <i>Curr Opin Immunol.</i> 2008; <b>20</b>(5): 530–7. <a target=xrefwindow id=d3524e5247 href="http://www.ncbi.nlm.nih.gov/pubmed/18555676">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5250 href="https://doi.org/10.1016/j.coi.2008.04.013">Publisher Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/3322956"><span class="faculty-opinion-icon small"></span></a><a name=d3524e5259 class=n-a></a>Hakkim A, Fürnrohr BG, Amann K, <i> et al.</i>: Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. <i>Proc Natl Acad Sci U S A.</i> 2010; <b>107</b>(21): 9813–8. <a target=xrefwindow id=d3524e5270 href="http://www.ncbi.nlm.nih.gov/pubmed/20439745">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5273 href="https://doi.org/10.1073/pnas.0909927107">Publisher Full Text </a> | <a target=xrefwindow id=d3524e5277 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2906830">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/3322956">Faculty Opinions Recommendation</a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d3524e5290 class=n-a></a>Knight JS, Subramanian V, O'Dell AA, <i> et al.</i>: Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/<i>lpr</i> mice. <i>Ann Rheum Dis.</i> 2015; <b>74</b>(12): 2199–206. <a target=xrefwindow id=d3524e5304 href="http://www.ncbi.nlm.nih.gov/pubmed/25104775">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5308 href="https://doi.org/10.1136/annrheumdis-2014-205365">Publisher Full Text </a> | <a target=xrefwindow id=d3524e5311 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4320672">Free Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d3524e5320 class=n-a></a>Macanovic M, Sinicropi D, Shak S, <i> et al.</i>: The treatment of systemic lupus erythematosus (SLE) in NZB/W F<sub>1</sub> hybrid mice; studies with recombinant murine DNase and with dexamethasone. <i>Clin Exp Immunol.</i> 1996; <b>106</b>(2): 243–52. <a target=xrefwindow id=d3524e5334 href="http://www.ncbi.nlm.nih.gov/pubmed/8918569">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5338 href="https://doi.org/10.1046/j.1365-2249.1996.d01-839.x">Publisher Full Text </a> | <a target=xrefwindow id=d3524e5341 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2200591">Free Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d3524e5350 class=n-a></a>Nakamura T, Ebihara I, Tomino Y, <i> et al.</i>: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. <i>Kidney Int.</i> 1995; <b>47</b>(2): 481–9. <a target=xrefwindow id=d3524e5361 href="http://www.ncbi.nlm.nih.gov/pubmed/7723234">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5364 href="https://doi.org/10.1038/ki.1995.61">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d3524e5374 class=n-a></a>Furumoto Y, Smith CK, Blanco L, <i> et al.</i>: Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. <i>Arthritis Rheumatol.</i> 2017; <b>69</b>(1): 148–60. <a target=xrefwindow id=d3524e5385 href="http://www.ncbi.nlm.nih.gov/pubmed/27429362">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5388 href="https://doi.org/10.1002/art.39818">Publisher Full Text </a> | <a target=xrefwindow id=d3524e5392 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5195893">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/725703355"><span class="faculty-opinion-icon small"></span></a><a name=d3524e5401 class=n-a></a>Wang H, Li T, Chen S, <i> et al.</i>: Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin. <i>Arthritis Rheumatol.</i> 2015; <b>67</b>(12): 3190–200. <a target=xrefwindow id=d3524e5412 href="http://www.ncbi.nlm.nih.gov/pubmed/26245802">PubMed Abstract </a> | <a target=xrefwindow id=d3524e5415 href="https://doi.org/10.1002/art.39296">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/725703355">Faculty Opinions Recommendation</a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d3524e5428 class=n-a></a>White WI, Seto NL, Playford MP, <i> et al.</i>: Alteration of mediators of vascular inflammation by anifrolumab in the phase iib muse study in sle. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(Suppl 2): 136–37. [Abstract]. <a target=xrefwindow id=d3524e5439 href="https://doi.org/10.1136/annrheumdis-2018-eular.3541">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 Aug 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-905&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-905&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong<br/> <p> <div class=margin-bottom> Susan Yung <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Desmond YH Yap <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Tak Mao Chan <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-905/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 04 Aug 2020, 9:905 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.22438.1">https://doi.org/10.12688/f1000research.22438.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Yung S <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=24760 data-id=22438 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22438.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-905/v1/pdf?article_uuid=0f84549e-a903-4c8b-bc81-b89fa4200693" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.22438.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Yung S, Yap DY and Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):905 (<a href="https://doi.org/10.12688/f1000research.22438.1" target=_blank>https://doi.org/10.12688/f1000research.22438.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=22438 id=mobile-track-article-signin-22438 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22438?target=/articles/9-905"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24760 /> <input name=articleId type=hidden value=22438 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Richard Furie</strong>, Division of Rheumatology, Northwell Health, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Scott E. Wenderfer</strong>, Pediatric Nephrology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 Aug 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-905&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-905&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73471-68623></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73470-68622></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-905/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>04 Aug 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Richard Furie</strong>, Division of Rheumatology, Northwell Health, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Scott E. Wenderfer</strong>, Pediatric Nephrology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-905&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-905/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "A review of advances in the understanding...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-905/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-905/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-905/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Yung S et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-905/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-905",
            templates : {
                twitter : "A review of advances in the understanding of lupus nephritis.... Yung S et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-905/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/22438/24760")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "24760");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "68623": 3,
                           "68622": 3,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "fcf89d03-d7ee-48d8-bd6d-34d42c35e728";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-905.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-905.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-905.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-905.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-905.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>